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Abstract
Determining the effects of phosphorylation
on AFAP-110 function.
Lidia N. Cherezova
AFAP-110 was discovered in late eighties as a 110-kDa protein that associates
with active Src in Src transformed cells. Since then it has been determined that AFAP110 is a actin cross-linking protein with an intrinsic ability to remodel actin cytoskeleton
in response to signals from active Src and PKC. AFAP-110 associates with Src via SH2
and SH3 interactions and with PKC via amino terminal PH domain. AFAP-110 binds
actin filaments directly, multimerizes via carboxy-terminal leucine zipper motif and also
possesses an intrinsic ability to remodel actin cytoskeleton. Therefore AFAP-110 may act
as a cellular effector for Src and PKC remodeling actin filaments in response to activation
of these kinases. AFAP-110 is hyperphosphorylated on serine and threonine residues in
active Src expressing cells and in cells subjected to PMA treatment in PKC-dependent
manner. PKC-dependent phosphorylation influences AFAP-110 multimerization mode as
well as its actin-cross linking abilities. Therefore it became important to identify
functional serine/threonine phosphorylation sites of AFAP-110.
As there are over twenty potential PKC phosphorylation sites in AFAP-110
structure, deletional mutagenesis was employed to determine which regions of AFAP110 are most likely to contain crucial sites for PKC phosphorylation. Our data indicate
that functional PKC phosphorylation sites must be localized to the amino acid stretch
266-294 within STK region of AFAP-110. There are four PKC candidate
phosphorylation sites in this region; they are being substituted by alanine residues in
order to determine their significance in serine/threonine phosphorylation regulation of
AFAP-110 function.
Analysis of AFAP-110 amino acid sequence has also revealed that AFAP-110
contains twelve potential 14-3-3 binding sequences. 14-3-3 proteins are a family of small
acidic adaptor proteins of dimeric nature that act as molecular scaffolds and/or allosteric
regulators in a number of cellular pathways. We have been interested to determine
whether 14-3-3 is a binding partner for AFAP-110 in vivo. We determined that AFAP110 associates with 14-3-3 in vivo, although it still remains unknown whether this
association is direct or facilitated by any of a multitude of 14-3-3 binding partners.
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Chapter 1

Serine/threonine phosphorylation of adaptor
proteins
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I. Introduction.
Phosphorylation of proteins is a reversible form of posttranslational modification
that occurs rapidly in response to cellular signals to regulate protein function.
Phosphorylated proteins often display conformational changes and/or altered ability to
interact with binding partners. Until recently tyrosine phosphorylation regulated proteinprotein interactions were the subject of thorough investigation while the sole
consequence of serine/threonine phosphorylation were thought to be allosteric
modifications. In the past few years it became apparent that serine/threonine
phosphorylation regulates protein-protein interactions not only via allosteric mechanism,
but also results in their ability to form complexes with phospho-serine/threonine specific
binding partners. Four phospho-serine/threonine binding domains that have been
identified are described below.
14-3-3 ligand binding groove was the first phospho-serine/threonine specific
binding domain to be identified (1). It represents a carboxy-terminal part of the 14-3-3
molecule with highly conserved residues lining the inner surface of a concave ligandbinding groove (2). Co-crystallization studies have confirmed the phosphorylation
specific nature of 14-3-3-ligand interactions (3). Most well-known consensus sequences
for 14-3-3 conserved binding groove are RSXpS/TXP and RXSXpS/TXP. Arginine in –3
or –4 position relative to phosphorylated serine or threonine is required, whereas serine in
–2 and proline in +2 are preferable. Serine or threonine in position 0 must be
phosphorylated for 14-3-3 to bind to a target protein. Phosphorylation of serine in –2
position does not enable 14-3-3 binding (4). 14-3-3 binds to a variety of signaling and
structural proteins, thus it may act as a scaffold to bring different target proteins into
complexes facilitated by its ability to form saddle-shaped dimers via interaction between
amino terminal parts of the two 14-3-3 molecules (2).
WW domains are relatively small 35-40 amino acid modules that bind prolinerich sequences PPXY or PPLP. Recently it became apparent that certain WW domains
bind target proteins in a phosphorylation specific manner. WW domains of prolyl
isomerase Pin1 and ubiquitin ligase Nedd4 have been shown to recognize pSer/Thr-Pro
motifs on target proteins (5). Pin1 is a prolyl isomerase, a protein whose function is cistrans isomerization of peptidyl-prolyl bond. Pin 1 differs from other prolyl isomerases as
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it is able to catalyze isomerization of pSer/Thr-Pro bond while it is known that
phosphorylation of Ser or Thr residue in Ser/Thr-Pro sequences reduces the rate of
isomerization for other prolyl isomerases (6).

WW domain of Pin 1 binds mitotic

phosphoproteins via interactions with p-Ser or p-Thr. This binding occurs in a
phosphorylation dependent manner for Pin 1 does not initiate binding to mitotic targets if
they were dephosphorylated. The crystal structure shows that the Pin 1 WW domain has a
hydrophobic cluster formed by different strands of β sheets (6). Co-crystallization of the
WW domain of Pin 1 with a phosphopeptide substrate show the structural basis for WWPhosphorylated target interactions (7). WW domain of ubiquitin ligase Nedd4 has also
been shown to associate with target proteins via phosphothreonine or phosphoserine
interactions, which are responsible for presentation of proteins for ubiquitination (5;6).
Forkhead associated domains (FHA) are conserved 55-75 amino acid modules
that were originally found in forkhead family transcription factors (8). They are present in
both eucaryotes and prokaryotes. FHA domain contains three highly conserved stretches
of amino acid separated by variable regions. Each conserved stretch contains invariable
residues in the middle of it – a Gly for the first and third, His for the second position. The
secondary structure of FHA has a β strand structure. The majority of FHA proteins
known today are nuclear proteins that fall into three categories – transcription factors,
DNA repair proteins or cell cycle proteins. Yeast FHA containing DNA repair protein
Rad53p is the best studied. It has two FHA domains, FHA1 and FHA2, both of which
bind to target proteins in a phosphorylation dependent manner, specifically recognizing
phospho-threonine (9;10). The FHA1 domain binds phospho-threonine containing
sequences within the consensus pTXXD, whereas FHA2 binds pTXXI (11;12). Other
FHA containing proteins display different preferences for amino acid in the +3 position
though it is clear that their binding to target proteins is phospho-threonine specific. Liao
and co-workers have shown that the FHA2 domain of Rad53p can also bind
phosphotyrosine containing targets (9). Their data suggest that FHA domains may be
dual specificity binding modules.
WD 40 motifs were originally discovered in the β subunit of heterotrimeric G
proteins (13). Since then they have been found in various other proteins. WD 40 motifs
represent regions of approximately forty amino acids. Their characteristic feature is that
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they always terminate with Trp-Asp (WD).

WD-40 motifs are always arranged in

tandem with sequence similarity among them. In the past few years a number of reports
indicated that WD-40 motifs of F-box containing proteins bind their target proteins in a
serine/threonine phosphorylation-dependent manner (5). F-box proteins are the ones
responsible for recognizing phosphorylated substrates and linking them to E3 ubiquitin
ligases. The biochemical data accumulated on F-box-protein interactions with their
substrates suggests that it is WD-40 repeat regions of F-box proteins that mediate F-box
protein binding to the substrate (14-17). Unlike for 14-3-3, WW and FHA domains, for
WD-40 domains no experiment has been performed to provide us with structural proof
that WD-40 indeed binds substrates in phospho-serine/threonine dependent manner.

II. Indirect effects: Serine/threonine phosphorylation of another protein enables it
to become a binding partner for an adaptor protein.

2.1 14-3-3
14-3-3 proteins are small acidic proteins with a molecular weight around 30kDa
(18). The 14-3-3 proteins are cellular components of all cells types that have been
examined, and they have been found in all vertebrates, invertebrates, plants, and fungi
(19;19-21) (20;21).

The 14-3-3 family of proteins includes seven unique isoforms,

named by Greek letters according to their elution order after reverse-phase highperformance liquid chromatography:β/α, ζ/δ, η, γ, τ, σ and ε (18;18;22;23). 14-3-3
proteins are highly conserved among each other and across different species although
they do have

differences in some regions (23;23;24). All 14-3-3 proteins are able to

dimerize, with the ability to form both homo- and heterodimers in vitro and in vivo
(21;21;25). Dimerization occurs via hydrophobic interactions between highly conserved
residues within amino-terminal parts of the molecules (18;18;22;23;23). Carboxy-termini
of two molecules brought together by dimerization create a ligand binding amphipathic
groove (4;4;26). Highly conserved residues form the inner surface of the binding groove,
whereas variable residues create the outer surface. This groove may bind either two
different molecules or bring together different regions of the same protein therefore
serving as a scaffold or allosteric regulator (26;27). The variant residues of the outer
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surface of the groove may provide specific binding surfaces for different proteins. 14-3-3
proteins bind two well-defined structural motifs on target proteins. The first contains
phosphoserine in the center with arginine, serine and proline in positions –3, –2, and +2,
respectively. Another one is defined as short amino acid sequence containing
phosphoserine in the center with arginine, aromatic residue, basic residue and proline at
positions –4, -2, -1, +2 respectively (4;4;18;28;28). 14-3-3 dimers could bind to several
phosphoserine-containing motifs on one protein or bring several target proteins together
as a consequence of binding to conserved motifs found on different proteins. 14-3-3
dimers also may act as molecular links between proteins bound to the conserved groove
and ones associated with variable outer surface, therefore performing a role of scaffolds
that regulate specific protein-protein interactions (26). 14-3-3 proteins have over 60 in
vivo binding partners (2). 14-3-3 proteins have been implicated in regulation of
serine/threonine kinases such Raf and PKC (19;19;22;29;30;30). 14-3-3 proteins bind Raf
and certain PKC isoforms directly and therefore serve to facilitate interactions between
these signaling proteins (27). 14-3-3 brings Raf into proximity with Bcr as well (2). Raf
is a key protein kinase in mitogen activated protein kinase cascade. Raf functions
downstream of growth factor receptor and Src-family non-receptor tyrosine kinases, and
Ras, and upstream of MAP kinase to transmit developmental and proliferative signals.
14-3-3 associates with Raf in vivo regardless of Raf subcellular localization or activation
status (18;19;31;32). Overexpression of 14-3-3 proteins has been shown to contribute to
Raf activation, although it is clear that 14-3-3 proteins are unable to activate Raf by
themselves (32;32). Some other reports stated that the nature of 14-3-3 influence on Raf1 is inhibitory (33;34;34). The data on Raf-14-3-3 interaction accumulated to date
suggests the following model of Raf-14-3-3 interaction: Raf has three 14-3-3 binding
sequences in its structure. 14-3-3 is bound to cytosolic Raf at amino-terminal and carboxy
terminal binding sites; this association serves to keep Raf in an inactive, although
activatable, state. Upon Raf activation by Ras the former undergoes translocation to the
membrane. The 14-3-3 dimer is displaced from the amino terminal binding site on Raf,
but it still associates with the carboxy terminal 14-3-3 binding site. Yet unidentified
kinases come along and phosphorylate the serine in the center of the intermediate 14-3-3
binding site of Raf and 14-3-3 binds to it, stabilizing Raf in an active state (4;4;30). 14-3-
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3 therefore has a dual role in Raf regulation, it keeps Raf in an inactive state in the
cytosol, but upon Ras-dependent Raf activation it stabilizes it in an active conformation.
14-3-3 proteins also have been shown to be both PKC substrates and regulatory proteins
(35;36). 14-3-3 may bind to Raf and PKC at the same time, therefore bringing Raf to
proximity with PKC to ensure phosphorylation of the former by the latter (18;18;27;37).
14-3-3 binding to a target protein often serves to keep that protein either in
inactive state and/ or sequester it from binding partners. 14-3-3 binds Cdc25C
phosphatase in a phosphorylation dependent manner via its RSXpSXP site –the perfect
consensus for 14-3-3 binding. This interaction is responsible for keeping this protein
inactive throughout G1, S and G2 phases of the cell cycle and also transports it from the
nucleus to cytosol (38;39). 14-3-3 bind the apoptotic protein BAD in a phosphorylation
dependent fashion. The function of this interaction is to sequester BAD in the cytosol and
keep it from binding to Bcl2 and also possibly protecting it from phosphatases (40). 14-33 binds IRS-1 and therefore prevents its association with PI3K (41).
Dubois and colleagues show that two unidentified brain kinases phosphorylate 143-3 on the sites located at C terminus of 14-3-3, a region where PI3K, Raf and Cbl bind
to 14-3-3 (42). Therefore, they speculate that phosphorylation regulates 14-3-3
interactions with binding partners. They also refer to the data of Aitken and colleagues
that leads to suggestion that 14-3-3 α and δ, which are phosphoisoforms of 14-3-3 β and
ζ, respectively, may influence PKC activity more strongly than their non-phosphorylated
counterparts(29). Later that year they followed with another publication where they
determined the identity of the brain kinase that phosphorylates Ser233 of 14-3-3 as casein
kinase 1 (43). Another kinase that utilizes 14-3-3 as a substrate is sphingosine dependent
protein kinase SDK1 (44). The function of 14-3-3 phosphorylation remains to be
determined.

2.2. p130Cas.
Crk associated substrate p130Cas was discovered over a decade ago as a
phosphotyrosine-containing binding partner for active Src and Crk (45). The Cas domain
structure along with variety of binding partners, suggests that it acts as an adaptor protein.
The domain structure from amino to carboxy terminus: SH3 domain, proline rich region,
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so-called “substrate-binding” domain that associates with adaptor proteins Crk, Nck and
SHIP, serine rich motif and a carboxy-terminal region that interacts with different protein
kinases and adaptor proteins (45). Cas is involved in regulation of cell motility,
cytoskeleton integrity, growth regulation, apoptosis, and Src and Crk dependent
transformation (45). Cas is localized to focal adhesions where it associates with Crk, Src
and FAK. FAK/Cas interaction occurs via proline-rich region of FAK and SH3 domain of
Cas (46;47). Cas forms a complex with Crk at focal adhesions; Cas/Crk complexes
influence cytoskeletal rearrangements in a Rac1-dependent manner (45;48).Focal
adhesions are the sites where actin stress fibers are linked to extracellular matrix. Focal
adhesions are also the sites of integrin signaling (49).
The data accumulated so far suggests that Cas is involved in the regulation of
cytoskeletal integrity, cell-matrix adhesion and cell motility. In Cas knockout cells actin
filaments are disorganized but formation of focal adhesions remains intact (50).
Cas, as well as FAK and paxillin, is phosphorylated on serine/threonine residues
in mitosis and concomitantly dephosphorylated on tyrosine residues (49). Mitosis is the
stage of the cell cycle when cells display actin filament disorganization and detachment
from the substratum. Mitotic phosphorylation of focal adhesion proteins must be a way of
cell detachment regulation. Serine phosphorylation of Cas and FAK during mitosis
promotes their dissociation from one another. Mitotic FAK is able to reassociate with
interphase Cas following ser/thr phosphatase treatment, therefore FAK/Cas interaction
does not depend on tyrosine phosphorylation of FAK as ser/thr dephosphorylated mitotic
FAK has no tyrosine phosphorylation. These data indicate that serine/threonine
phosphorylation of FAK and not its tyrosine phosphorylation regulates FAK/Cas
complex formation (49).

Ma and co-workes confirm that serine/threonine

phosphorylation of FAK down-regulates its ability to form a complex with Cas (51). The
physiological significance of serine/threonine phosphorylation of Cas itself remains to be
determined.

2.3. AP-2
Adaptor protein 2 is a multisubunit adaptor protein complex associated with
endocytic clathrin coated vesicles. AP2 associates with proteins like EGF receptor
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substrate Eps15 and Epsin at the membrane. This association is disrupted in mitosis when
both Eps15 and Epsin are phosphorylated on ser/thr residues. Eps15 and Epsin are
substrates for p34Cdc2 in vitro. Ser/thr phosphorylation of epsin and Eps15 results in
dissociation of these proteins from AP2 complex. This may provide a mechanism that
inhibits clathrin-mediated endocytosis in the stage of mitosis (52;53).

III. Adaptor proteins that are serine/threonine phosphorylated but function of
phosphorylation remains to be determined.

3.1. Chat.
Chat is a Cas/HEF-1 associated adaptor protein isolated by Sakakibara and
Hattori last year (54). The function of Chat itself as well as the function of its
phosphorylation has not been determined. Sakakibara and Hattori show that Chat binds
the adaptor protein Cas directly, and this interaction is phosphorylation-independent (in
vitro binding assay). Chat has multiple serine/threonine residues, four of which comprise
potential MAPK sites (PXS/TP). Phosphorylation levels of Chat increase in response to
growth factor treatment, and it is not due to tyrosine phosphorylation (there is a gel shift
in response to GF treatment, but pTyr Ab does not react with the upper portion). MAP
kinase may be the one responsible for GF mediated phosphorylation of Chat as MAPK
inhibition results in the disappearance of the slower migrating band. Overexpression, but
not phosphorylation, of Chat up-regulates JNK activity in a manner similar to that of Cas.
Chat is a cytoplasmic protein, but in response to GF stimulation it moves to membrane
ruffles where it colocalizes with actin (54).

3.2. NHERF.
NHERF is a Na+/K+ exchange regulatory factor that was discovered several years
ago and since then it became apparent that this is an adaptor protein. NHERF contains
two PDZ domains in tandem where the majority of NHERF binding partners associate,
along with the carboxy-terminal region that binds ERM proteins. NHERF proteins are
localized to the plasma membrane, where in addition to already mentioned function as
Na+/K+ exchange regulators they also regulate transmembrane receptors and are
involved into growth factor receptor signaling (55).
8

In 1995 Weinman and colleagues suggested that NHERF may be a substrate for
serine/threonine phosphorylation for they found potential sites for PKA phosphorylation
in the C-terninus of NHERF (56). A more recent report by Hall and co-workers shows
that NHERF is constitutively phosphorylated on serine/threonine residues, and that
NHERF is a binding partner and an in vitro substrate for a G protein receptor coupled
kinase GRK6A (57). The functional significance of NHERF phosphorylation remains to
be determined.
NHERF proteins are able to dimerize. The physiological significance of this
capability still remains to be determined. The ability of NHERF proteins to dimerize is
greatly diminished in response to okadaic acid treatment. It seems therefore that protein
phosphorylation might be responsible for regulation of the ability of NHERF proteins to
self-associate, although it is not known at this point whether phosphorylation of NHERF
themselves or NHERF binding partners influenced this effect (58).

3.3. Nck/Dock
Nck is an adaptor protein that was discovered in 1990 (59). Its domain structure
suggests that it serves as an adaptor protein. Nck has three SH3 domains in tandem
followed by an SH2 domain at the carboxy-terminus. Indeed, it binds a variety of target
proteins such as protein kinases, adaptor and motor proteins, involved in regulation of
actin filaments integrity, DNA synthesis, transcription and translation as well as protein
degradation (reviewed in (60).
Two reports published in 1992 show that Nck is phosphorylated in growing cells
and in response to PMA or growth factor stimulation of cultured cells (61;62).
Phosphoamino acid analysis has demonstrated that Nck is phosphorylated predominantly
on serine/threonine with one tyrosine phosphorylated peptide recovered. Neither the
identity of serine/threonine kinase nor the physiological role of serine/threonine
phosphorylation of Nck was determined (61;62).

3.4. Grb7.
Grb7 is a 535 amino acid protein with similarity to Grb2, Shc and Nck. Grb7
family includes Grb7, Grb10 and Grb14 proteins. Grb7 proteins contain several protein-
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protein interaction modules such as proline-rich, PH, Ras-associating, and SH2 in their
structure, which enable them to interact with a variety of signaling proteins and therefore
serve as adaptors linking receptor activation to downstream signaling pathways (63).
Grb7 is able to form homo- or heterodimers and larger complexes (64). Dimerization of
the Grb7 family of proteins may serve to bring signaling proteins together into large
complexes. Grb7 family of adaptors has been implicated in the regulation of cell
proliferation, cell motility, apoptosis and tumorigenesis (63).
The Grb7 family of adaptor proteins is constitutively phosphorylated on
serine/threonine residues, and the level of their serine/threonine phosphorylation
increases in response to EGFR and heregulin receptor stimulation (65-67)). The
functional significance of this phosphorylation remains to be determined.

IV. Direct effects: Serine/threonine phosphorylation of an adaptor protein recruits
in a binding partner for it.

4.1. Paxillin.
Paxillin was initially discovered as a tyrosine phosphorylated protein from Src
transformed cells (68). Paxillin is localized to focal adhesions, where it serves as a
scaffold for a wide variety of signaling and structural proteins. The ability of paxillin to
bind various proteins is attributed to several protein-protein interaction domains - i.e.,
LD motifs and SH2 and SH3 binding motifs in the amino terminus and four LIM
domains in the carboxy terminus. LD motifs are conserved eight amino acid leucine rich
sequences (LDXLLXXL), serving as binding sites for a number of paxillin binding
partners such as FAK, vinculin, and PYK2. LIM domains are double zinc finger motifs
approximately 50 amino acids long whose function is to serve as protein-protein binding
modules. LIM domains of paxillin promote its localization to the plasma membrane via
association with integrins. Paxillin is crucial for embryogenesis since paxillin knockout
mice die on the seventh-eighth day of embryogenesis (69). Paxillin deficient cells display
an inability to spread (70).
Tyrosine phosphorylation of paxillin and its functional significance has been
extensively studied for some time, while serine/threonine phosphorylation has started to
draw attention only recently. Paxillin is phosphorylated on serine residues in vivo in
10

response to plating of cultured cells on vitronectin or fibronectin, and also in mitosis and
in MCF-7 cells in response to heregulin stimulation (49;71-73). The identity of
serine/threonine kinases that phosphorylate paxillin in vivo is unknown although it is
known that paxillin is serine phosphorylated in response to PKC activation following
PMA treatment and treatment with a PKC inhibitor reduces paxillin serine
phosphorylation (71). The fact that paxillin is phosphorylated upon adhesion of cells to
ECM was confirmed by (74). Their work is cell type specific for EL4 cells, which
represent murine thymoma cell line. These cells display an ability to adhere in response
to PMA treatment. PMA treatment also results in serine phosphorylation of paxillin. The
signaling cascade may proceed from PMA stimulation via MEK/ERK pathway to
adhesion. If a specific inhibitor of MEK activation is added, there is a reduction in a
number of adherent cells. ERK is one (though not only) kinase that is activated
downstream of PKC in these cells. MEK/ERK inhibitor abolished PMA induced paxillin
phosphorylation leading to the suggestion that the proceeds from PKC via MEK/ERK
pathway to paxillin. Paxillin is a substrate for ERK2 in vitro (74). Recent data of
Hashimoto and co-workers indicate that paxillin associates with PAK3 and serves as a
substrate for this kinase in vitro (75).
Paxillin has four LIM domains in its carboxy terminus. GST-LIM2 and GSTLIM3 constructs were phosphorylated on threonine or serine, respectively, in vitro
(whereas GST-LIM1 and GST-LIM4 were not). Site directed mutagenesis was employed
to identify phosphorylation sites within LIM2 and LIM3 domains. LIM3 and LIM2
become phosphorylated during cell adhesion to fibronectin in vivo. Phosphorylations of
LIM domains of paxilllin promote localization of this protein to focal adhesions. Certain
site-directed mutants of paxillin, which have serine or threonine mutated to alanine or
valine, respectively, do not localize to focal adhesions as efficienltly as a wild type, and
as a result these cells adhere to fibronectin poorly. Serine/threonine phosphorylations of
LIM domains bring paxillin to newly created focal adhesions (76).
Serine/threonine phosphorylation of paxillin also has a role in cell movement,
which was described in a paper by Vadlamudi and colleagues (73). They found that
MCF-7 cells invasiveness is increased in response to heregulin exposure. Along with this,
in response to heregulin treatment paxillin becomes phosphorylated on serine and
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threonine residues (73) as demonstrated by SDS-PAGE mobility shift, phosphoamino
acid analysis and serine/threonine phosphatase versus tyrosine phosphatase treatments;
the latter does not interfere with heregulin induced phosphorylation of paxillin (73). This
group of researchers found that two pools of paxillin are present in MCF-7 cells: one of
them is co-localized with focal adhesions, while the other is cytoplasmic. Heregulin
treatment causes relocation of paxillin from focal adhesions to perinuclear areas of the
cytoplasm accompanied by changes in cell shape. Serine/threonine phosphorylation of
paxillin and accompanying cell scattering are dependent upon p38MAPK rather than
p42/44MAPK pathway activation, which has been demonstrated by use of specific MEK
inhibitors. Overall, these data indicate that heregulin treatment leads to paxillin relocation
from focal adhesions, that promotes their disassembly, which is necessary for cell
movement to occur (73).

4.2. Gab1.
The name Gab1 stands for Grb2 associated binder 1. In response to insulin,
cytokine or growth factor stimulation (HGF, EGF, NGF, PDGF) Gab1 becomes
phosphorylated on tyrosine and binds the tyrosine-phosphorylated receptor directly, or
indirectly via Grb2 in a phosphorylation dependent manner (77). Gab1 has an amino
terminal PH domain that tethers Gab1 at the membrane via PIP3 interaction and carboxy
terminal Met binding domain (MBD) that mediates direct interaction of Gab1 with cMet,
and also has binding sites via which it interacts with SH3 domain of Grb2. There are 21
tyrosine residues in between these two regions, which upon phosphorylation serve as
docking sites for a number of binding partners. The list of Gab1 binding partners
includes Grb2, cMet, p85 subunit of PI3K, PLCγ, Shc, Shp2 phosphatase, Crk and CrkL
(77-79).
Phosphoaminoacid analysis of Gab1 overexpressed with dominant negative or
positive MEK shows that serine/threonine phosphorylation levels of Gab1 are elevated in
response to co-expression with constantly active MEK. Gab1 binds phosphorylated
ERK2 directly and phosphorylated by it; Gab1 also associates with phospho-Erk1 in
response to MEK activation (80). Several years later this same group of authors followed
with another report, which demonstrates that cMet activation results in MAPK cascade
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activation, and Gab1 becomes phosphorylated by active ERK2 followed by recruitment
of PI3K to the membrane (78). Consequently, Akt activation follows in response to PI3K
activation as a result of an association with Gab1. They state that Gab1 has to be
phosphorylated both on threonine and tyrosine residues to ensure for PI3K association
(78).
Okadaic

acid

treatment

of

cultured

cells

results

in

serine/threonine

phosphorylation of Gab1 (81). One of the effects of cMet stimulation by HGF is cell
scattering, which is the result of c-Met stimulated increased cell motility. Okadaic acid
treatment of cultured cells prior to HGF stimulation prevents cell scattering. Under these
conditions Gab1 is found to be hyper-phosphorylated on serine and threonine residues
and hypo-phosphorylayed on tyrosine residues. Okadaic acid promoted decrease in
tyrosine phosphorylation of Gab1 is a consequence of its elevated serine/threonine
phosphorylation which by some undetermined mechanism prevents cMet form
interacting with and phosphorylating Gab1 (81) .
Serine/threonine phosphorylation results in

Gab1 association with 14-3-3. The

functional significance of this interaction remains to be determined, as it does not seem to
interfere with Gab1/Met1 interactions and therefore sequester Gab1 from the membrane.
Okadaic acid activates MAPK and PKC by inhibition of serine/threonine phosphatases.
Using pharmacological agents that are known to be specific inhibitors of MAPK pathway
or PKC kinase, they show that for serine/threonine phosphorylation of Gab1 in response
to okadaic acid treatment is PKC dependent. Phorbol ester treatment results in a decrease
of both electrophoretic mobility and tyrosine phosphorylation levels of Gab1. Gab1 is a
substrate for conventional PKC isozymes in vitro. PKC inhibitor staurosporine treatment
restores cell scattering inhibited by okadaic acid (81). The authors hypothesize that
serine/threonine phosphorylation alters Gab1 conformation so that tyrosine residues
cannot be presented for phosphorylation; as a consequence, the docking sites for binding
partners are not being created which results in Gab1 inability to associate with them (81) .

4.3. PECAM-1.
Platelet endothelial cell adhesion molecule 1 (PECAM-1) is a transmembrane
glycoprotein belonging to immunoglobulin family of adhesion molecules that is
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expressed only in hematopoetic and vascular cells. Upon phosphorylation of tyrosines
within its ITAM motif it becomes a binding partner for PI3K, PLCγ, SHP1 and 2, Stat5a,
and cell-cell junction proteins catenins β and γ (82-84). PECAM-1 is phosphorylated not
only on tyrosine but also on serine and threonine residues. The levels of serine/threonine
phosphorylation of PECAM-1 are elevated in response to LPS treatment of monocytes in
a PKC dependent manner, which is demonstrated by the observation that PKC inhibitor
treatment downregulates LPS induced serine/threonine phosphorylation of PECAM-1
(85).

Along

with

PECAM-1

serine/threonine

phosphorylation

LPS

induces

transendothelial migration of monocytes. Phosphorylation of PECAM-1 on serine and
threonine residues appears to be connected to cell migration, this conclusion comes from
the fact that PKC inhibitor treatment blocks monocyte migration through the endothelial
cell layer (85). Phosphatase inhibitor treatment up-regulates both PECAM-1
serine/threonine phosphorylation and transendothelial movement of monocytes. These
data suggests that PECAM-1 may be involved in the regulation of monocytes movement
(85).
PECAM-1 is able to associate with both β and γ catenins (82). Serine/threonine
phosphorylation of PECAM-1 has been shown to down regulate its ability to associate
with γ catenin (83). PECAM1 is a substrate for PKC in vitro and phosphorylated on
serine/threonine residues in response to PKC activation in vivo (83). In response to PKC
activation by DAG a decrease in PECAM-1 interaction with γ catenin is observed,
whereas PKC inhibitor bisindolylmaleimide treatment promotes this interaction. PKC,
therefore, may be the kinase responsible for serine/threonoine phosphorylation of
PECAM-1 in vivo and PKC dependent serine/threonine phosphorylation of PECAM-1
may be a mechanism of regultion PECAM-1/γ catenin interactions. Experiments of Ilan
and colleagues suggest that one of the functions of PECAM-1 may be to bring catenins to
adherence junctions (83); PECAM-1 interaction with γ catenin is thought to link
PECAM-1 to the cytoskeleton via vimentin and therefore participate in transduction of
signals that regulate cell migration (83).
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4.4. Sos.
In response to growth factor stimulation receptor tyrosine kinases will
autophosphorylate on tyrosine residues, creating binding sites for the adaptor proteins
Grb2 and Shc. They, in turn, recruit a protein named Son of sevenless (Sos) to the
membrane. Sos protein is a guanine nucleotide exchange factor for Ras. Once at the
membrane, Sos promotes GDP to GTP exchange on Ras, activating it. Sos links growth
factor receptor activation to Ras stimulation (86). It was determined several years ago
that Sos1 is phosphorylated in response to EGFR stimulation (87). Phospho amino acid
analysis determined that Sos is phosphorylated predominantly on serine and to the lesser
extent on threonine residues, while no tyrosine phosphorylation was detected (88). It was
observed that the C terminus of Sos contains potential sites for MAPK phosphorylation.
Indeed, using phosphotryptic-mapping analysis it was demonstrated that Sos is a
substrate for MAP kinase both in vitro and in vivo, and the sites of phosphorylation were
identified (89;90). Since it has been determined that Sos protein is serine/threonine
phosphorylated, researchers have been trying to elucidate the functional significance of
Sos phosphorylation. Rozakis-Adcock and co-workers demonstrated that serine/threonine
phosphorylation of Sos downregulates Sos-Grb2 association with EGFR and Shc
although does not affect Sos interaction with GST-fused Grb2 (88). Corbalan-Garcia and
colleagues discovered that in response to being phosphorylated Sos dissociates from
Grb2.

The data accumulated by the two groups must be somewhat controversial, which

might be explained by the differences in exprerimental setup and also by the fact that
these groups of authors used Sos from different species (either human or murine) in their
experiments. Both groups agree that MAPK dependent Sos phosphorylation serves as a
feedback mechanism of Ras/MAPK pathway regulation. Sos is phosphorylated in MAPK
cascade dependent manner by active MAP kinase and supposedly by other
serine/threonine kinases that are activated downstream of MAPK pathway (88;89).
In T cells the MAPK cascade is activated in response to TCR ligation. Both TCR
activation and PMA stimulation result in serine/threonine phosphorylation of Sos-1; this
is demonstrated by reduced mobility of Sos-1 derived from PMA stimulated cells (91).
The mobility shift is lost if phosphatase treatment has been applied to Sos-1 from PMA
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treated cells. In T cells serine/threonine phosphorylation of Sos-1 is not MAPK cascade
dependent, this conclusion comes from the observation that MEK inhibitor treatment
does not result in decrease in serine/threonine phosphorylation levels of Sos-1 promoted
by TCR engagement. Mutation of seven potential MAPK consensus sites does not
diminish ability of Sos-1 to be phosphorylated on serine/threonine residues either (91).
It is well known that prolonged exposure to PMA results in depletion of cellular
pool of PKC due to its subsequent ubiquitination (92;93). When cells that had undergone
16-hour PMA treatment were subjected to TCR stimulation no serine/threonine
phosphorylation of Sos was detected. The same result was observed in cultured cells pretreated with specific PKC inhibitors (91). Therefore, PKC may be a Sos kinase in vivo.
Phosphorylation of Sos did not lead to its uncoupling from Grb2 under described
conditions, which is in agreement with previous data of Rozakis-Acock and co-workers.
Zhao and colleagues did not attempt to clarify the functional significance of Sos
phosphorylation (91).

4.5. Cbl.
c-Cbl is an adaptor protein that is ubiquitously expressed and known to be
phosphorylated on tyrosine residues (94). Cbl has several modular domains including a
zinc ring finger motif, SH2 and SH3 binding motifs and leucine zipper motif. These
modules facilitate the association of Cbl with 40 target proteins, among which are
receptor and non-receptor tyrosine kinases, E2 ubiquitination enzyme, p85 subunit of PI3
kinase, and adaptor proteins such as Crb2, Nck, and Crk. Cbl has the ability to form
dimers via its carboxy-terminal leucine zipper motif. T cell receptor activation leads to
tyrosine phosphorylation of Cbl and its transient association with CrkL and the p85
subunit of PI3K (94;95). P85 binds Cbl directly but it cannot bind CrkL, unless it
associated with Cbl that brings it into a close proximity with CrkL. Cbl has to be tyrosine
phosphorylated to perform this function. Cbl, therefore, act as a scaffold that brings PI3K
and CrkL together (95).
Liu and co-workers found that TCR ligation leads to serine/threonine
phosphorylation of Cbl upon which Cbl becomes associated with 14-3-3 (96). Cbl
interaction with 14-3-3 is direct and occurs only in response to TCR (96) or CD43 (97)
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ligation; while in unstimulated cells there is no Cbl-14-3-3 complex detected. 14-3-3
displaces PI3K from Cbl. Serine/threonine phosphorylation of Cbl has also been shown
to downregulate its tyrosine phosphorylation and association with another partner, the
adaptor protein CrkL (96). PMA treatment promotes serine/threonine phosphorylation of
Cbl and its consequent association with 14-3-3. Pretreatment of cells with specific PKC
inhibitors prior to PMA treatment results in an inability of PMA to induce
serine/threonine phosphorylation of Cbl. Cumulatively, these data suggest that Cbl
phosphorylation may be PKC dependent (95;97;98). PMA treatment also results in a
decrease in tyrosine phosphorylation levels of Cbl and therefore promotes its dissociation
from p85 and CrkL. Recent work of Pedraza-Alva and co-workers shows that CD43
receptor cross-linking causes Cbl association with Vav and PI3K; the latter is activated in
response to this interaction event (97). It is noteworthy that Cbl does not have to be
phosphorylated on tyrosine residues for described CD43 induced interactions to occur, as
there is no tyrosine phosphorylation of Cbl detectable under those conditions. PedrazaAlva and colleagues attempted to gain an insight into the functional significance of
serine/threonine phosphorylation of Cbl (97). It has been known for some time that
overexpression of Cbl has an inhibitory effect on receptor-mediated MAP kinase
activation. PKC dependent phosphorylation of Cbl followed by its association with 14-33 is thought to block the negative effect of Cbl on MAP kinase cascade activation (97).
Serine/threonine phosphorylation of Cbl also negatively regulates Cbl tyrosine
phosphorylation and therefore hampers its interaction with PI3K, CrkL and other
phosphotyrosine binding partners. All the data on Cbl serine/threonine phosphorylation is
T cell specific. Cumulatively, it leads to the conclusion that adaptor protein Cbl is
phosphorylated on tyrosine and serine/threonine via two separate receptor-signaling
pathways. Phosphorylation on either tyrosine or serine/threonine residues may enable Cbl
to associate with different set of binding partners and therefore be engaged in either one
of the two signaling cascades descending from the T cell receptor.
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4.6. IRS1.
Insulin receptor substrate 1 is a 165-185 kDa protein that associates with SH2
containing proteins in a phosphorylation dependent manner.

IRS1 becomes

phosphorylated on tyrosine residues by insulin receptor and consequently associates with
PI3 kinase, activating the latter. PI3 kinase activation results in activation of Akt/PKB,
which sends the signal further downstream. The physiological consequences of insulin
receptor signaling are glucose uptake and glycogen synthesis. In response to PDGF (in a
PI3K/Akt dependent manner) (99;100) or endothelin-1 (in a PKC and MAPK dependent
manner) (100) stimulation IRS1 becomes phosphorylated on serine residues, four of
which are MAPK consensus sites (101). Serine phosphorylation of IRS1 leads to the
decrease in its tyrosine phosphorylation levels (99;100) and IRS1/PI3K complex
disengagement (100;102) therefore inhibiting insulin receptor signaling. PDGR receptor
stimulation results in inhibition of insulin receptor signaling, cased by inability of IRS-1
to be tyrosine phosphorylated and form a complex with PI3K. The IRS1 mutant, which
has four serine residues substituted by alanines, retains the ability to be tyrosine
phosphorylated in response to insulin treatment in the presence of PDGFR stimulation
and associate with PI3K, activating it. In response to Akt activation IRS1 association
with PI3K is abrogated. It is not known yet whether Akt phosphorylates IRS-1 directly or
simply promotes IRS-1 phosphorylation by activating serine/threonine kinase(s)
downstream of it (100). Whatever the mechanism might be, attenuation of insulinreceptor signaling by active Akt suggests a model for negative feedback loop where PI3
kinase, activated in response to insulin-receptor stimulation via IRS-1 interaction, in turn
activates Akt, which comes along and phosphorylates IRS-1 causing dissociation of IRS1/PI3K complex (100).
Ogihara and colleagues (103) and Staubs and co-workers (99) observe
serine/threonine phosphorylation of IRS1 in response to PI3K association promoted by
insulin receptor activation. IRS1 is a substrate for PI3K in vitro (104;105). These data
suggests that PI3 kinase itself may be responsible for an attenuation of insulin receptor
signaling. Ogihara and co-workers also suggest that serine phosphorylation of IRS1 may
lead to presentation of phospho tyrosines for tyrosine phosphatases therefore enabling
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attenuation of insulin signaling (103).
Decrease in tyrosine phosphorylation of IRS1 was also observed in response to
PMA treatment of cultured cells (106). Activation of endogenous PKC by phorbol ester
treatment inhibits insulin receptor-mediated tyrosine phosphorylation of IRS-1. It has not
been demonstrated whether IRS1 is a substrate for PKC either in vitro or in vivo (106).
PKC is known to activate ERK1/2 in response to its activation. IRS1 is a substrate
for ERK1/2 in vitro (107). IRS1 contains four potential MAPK sites of a consensus
PXS/TP. PKC activates ERK1/2 in Raf-1 dependent manner. Both ERK1/2 and Raf
activation result in decreased insulin receptor mediated tyrosine phosphorylation of IRS1
in vivo, resulting in diminished IRS1/PI3K association (107).
Both insulin and PDGF receptor activation lead to PI3 kinase activation by
different mechanisms, which are responsible for different outcomes. IRS-1 is a key player
in insulin receptor signaling as it activates PI3K via association with it and thereby
triggers insulin-receptor mediated physiological events. PDGF receptor activates PI3
kinase via another pathway and causes PI3K dependent serine/threonine phosphorylation
of IRS-1, interfering with insulin receptor signaling. Serine/threonine phosphorylation of
IRS-1 was observed in response to activation of insulin receptor, which is in agreement
with the statement that serine/threonine phosphorylation of IRS-1 may provide the means
for a negative feedback regulation of insulin receptor signaling.

4.7. pShc66.
Shc is a ubiquitously expressed adaptor protein, which plays an important role in
growth factor receptor signaling. Upon tyrosine phosphorylation by ligand-activated
receptor tyrosine kinases Shc becomes a docking molecule for Grb2 allowing Grb2 to
bring Ras-GTP Sos to the membrane. Three isoforms of Shc are known – two of them,
p46 Shc and p52 Shc are synthesized from the same transcript (starting sites differ),
whereas p66 Shc is a result of alternative splicing (108;109). The three members of Shc
family may have different biological functions (109;110). p66 Shc, for example, plays a
role in regulation of oxidative stress response and life span in mice (111). Shc66
knockout mice have a prolonged life span and increased resistance to oxidative stress
(111). p46 Shc and p52 Shc cannot substitute for the p66 defect in p66Shc deficient
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mice. Oxidative stress response mediated by p66 Shc is serine phosphorylation
dependent, which is demonstrated by the fact that non-phosphorylated p66Shc cannot
revert mice to a normal phenotype (111). EGFR stimulation results in both tyrosine and
serine/threonine phosphorylation of the p66Shc isoform in CHO cells, which is
demonstrated by a mobility shift characteristic of serine/threonine phosphorylation.
Moreover, p66Shc has to be phosphorylated on tyrosine prior to serine/threonine
phosphorylation. Serine/threonine phosphorylation of p66Shc is /MAPK cascade
dependent, although the identity of the kinase is unknown. Upon serine/threonine
phosphorylation the ability of p66Shc to bind EGFR is abolished, although it is still able
to associate with Grb2. p66Shc competes with p52Shc for Grb2 as the amount of Grb2 in
cells is limiting. Therefore, in response to serine/threonine phosphorylation p66Shc
carries Grb2 away from the EGFR. Overexpression of p66 Shc inhibits ERK activation
(112). These data suggest the existence of a negative feedback regulation of EGFR
signaling. EGFR ligation leads to engagement of Shc/Grb2/Sos complex via which
activation of Ras/Raf/ MEK/ERK cascade occurs.

Serine/threonine phosphorylation of

p66Shc leads to disengagement of Shc/Grb2 complex from the EGFR leading to
attenuation of the EGFR signaling (112). In mesangial cells p66Shc is serine/threonine
phosphorylated in response to endothelin-1 receptor stimulation (113). p66Shc
serine/threonine phosphorylation occurs in response to ERK1/2 activation although the
identity of kinase that phosphorylates Shc66 under these conditions is unknown. Serine
phosphorylation of p66Shc brings it into proximity with three proteins two of which
remain to be identified and the third is 14-3-3 (113). Function of p66Shc association with
14-3-3 remains unknown. As 14-3-3 is known to bind a wide variety of proteins, and the
14-3-3 dimer is capable of binding two different proteins at once, it may either bring
p66Shc into proximity with some yet unidentified binding partner(s) for undetermined
purpose or simply to sequester p66Shc from the membrane, preventing it from competing
with two other Shc isoforms for Grb2 pool.
Taxol, an antitumor agent that has already been approved for treatment of breast,
lung, and ovarian carcinomas, causes serine/threonine, but not tyrosine, phosphorylation
of pShc66 in human lung carcinoma cells (114). Serine/threonine phosphorylated p66Shc
prevents it from interacting with Grb2. Although phosphorylation of Raf-1 and ERK1/2
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is observed simultaneously with p66Shc phosphorylation, these kinases are not
responsible for serine/threonine phosphorylation of pShc66. Taxol-mediated serine
phosphorylation of p66Shc is protein synthesis dependent, as cycloheximide treatment
inhibits taxol-induced phosphorylation of p66Shc and Raf-1. These data lead to
hypothesis that taxol-inducible p66Shc activation occurs in response to stimulation of yet
unknown signaling pathway, different from the MAP kinase cascade (114).
Taxol is a microtubule-interacting agent that is capable of arresting cell in mitosis
and it also has an apoptotic effect. As the serine/threonine phosphorylation of Shc reaches
maximum at 9-18 hours after treatment, when cell may be in the mitotic stage, the
authors speculate that Shc66 ser/thr phosphorylation may be responsible for transducing
an apoptotic signal (114) referring to the fact that Ser→Ala substitution of p66 Shc
enhances resistance to apoptosis (111).

V. Direct effects: Serine/threonine phosphorylation of an adaptor protein alters its
conformation and subsequent function.

5.1. Cortactin.
Cortactin was initially identified as a tyrosine phosphorylated substrate of active
Src (115). Cortactin has an amino terminal acidic (NTA) domain followed by a region of
cortactin repeats; alpha-helical domain, proline rich motif containing tyrosines, serine and
threonine residues in abundance and a carboxy-terminal SH3 domain (116). Cortactin is
localized to cortical actin structures. Recently it has been found that cortactin is involved
in regulating cell motility (117). Cortactin’s structure along with its localization and
ability to bind actin, suggests that this protein may be positioned to link signaling events
such as growth factor receptor activation to actin filament reorganization(118). Cortactin
is found to be phosphorylated in response to growth factor receptor stimuli.
Phosphorylation therefore may play a role in regulation of its function (116).
Van Damme and co-workers in 1997 have shown that in response to EGF
receptor stimulation of cortactin over expressing human squamous carcinoma cell line
p80 cortactin is converted into p85 cortactin and this conversion is a result of
phosphorylation (119).

Phosphoamino acid analysis has shown that EGF-induced
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cortactin phosphorylation occurs predominantly on serine and threonine residues.
Immunofluorescence analysis indicated that upon growth factor induced phosphorylation
cortactin relocates from perinuclear space to cell-matrix adhesion zone.
Campbell and colleagues show that endogenous p80 cortactin is converted into
the p85 form in response to EGF stimulation, confirming van Damme and co-workers
data. They also show that cortactin phosphorylation is ERK dependent since pretreatment with the specific MEK inhibitor PD98059 abolishes EGF-induced cortactin
phosphorylation. Active MEK is sufficient to cause cortactin phosphorylation but
insufficient to prevent basal phosphorylation of cortactin which suggests that there are
ser/thr kinases other than MAPK that phosphorylate cortactin in vivo. Proline-rich region
have been shown to contain phosphate acceptor sites as it can be phosphorylated by Erks
when expressed on its own (120). Although the role of serine/threonine phosphorylation
of cortactin still remains to be determined, from data described above it is possible that
phosphorylation of cortactin may regulate its subcellular localization. Campbell and coworkers speculate that the proline-rich domain of cortactin may interact with its own SH3
domain and therefore keep cortactin in a “closed” conformation. Serine/threonine
phosphorylation of a proline-rich domain will result in abrogation of this interaction
resulting in cortactin transition into the “open” conformation (120). Alternatively, ser/thr
phosphorylation of the proline rich region of cortactin may disrupt its interaction with
SH3 binding partners. The physiological significance of cortactin serine/threonine
phosphorylation as well as its impact on conformation remains to be determined.

5.2. AFAP-110.
AFAP-110 was first identified as a 110-kDa protein that co-immunoprecipitated
with active Src in Src-transformed cells (121). In normal cells AFAP-110 co-localizes
with actin stress fibers and the cortical actin matrix, frequently identified along the
leading edge of the cell. AFAP-110 has several protein-protein interaction modular
domains such as WW domain, SH2 and SH3 binding motifs, serine threonine kinase
interaction domain, pleckstrin homology (PH) domains, leucine zipper motif, and
carboxy terminal actin binding domains (122). AFAP-110 binds actin filaments directly
via its carboxy-terminal actin binding sequences, and it associates with Src via SH2/SH3
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interactions. The amino-terminal PH domain of AFAP-110 has been shown to facilitate
its interactions with PKC (Qian et al, manuscript in preparation). AFAP-110 therefore
may serve as an adaptor protein linking Src and PKC kinase activation to actin
cytoskeleton reorganization.
AFAP-110 has the capability to self-associate via interactions enabled by its
carboxy-terminal leucine zipper motif. In non-transformed cells it exists in multiple
forms including monomers, dimers, trimers, tetramers and even larger complexes. Upon
co expression with active Src (Scr527F), AFAP-110 is detected as dimers, but not in larger
complexes. Moreover, AFAP-110 self-association mode is altered in response to coexpression with active Src. Normally, GST-tagged c-terminus of AFAP-110 is able to
affinity absorb AFAP-110 from cell lysates; in response to co-expression with active Src
this ability is diminished almost completely. These data indicate that active Src causes a
conformational change in AFAP-110 responsible for alteration in leucine zipper motif
mediated self-association (123). It is also known that this alteration in AFAP-110 selfassociation occurs is a result of serine/threonine phosphorylation, as AFAP-1105Y mutant
which has five tyrosine residues, phosphorylated by Src in active Src expressing cells,
changed to phenilalanine ones so this mutant can neither be phosphorylated by nor even
interact with Src and yet the ability of GST-Cterm to pull down AFAP-1105Y is decreased
in response to co-expression with active Src in a manner identical to that of wild type
AFAP-110 (Baisden and Flynn, unpublished data). It has been hypothesized that Src
activates serine/threonine kinases one of which may be PKC, and these kinases come
along and phosphorylate AFAP-110 on serine and threonine residues. Indeed, in response
to PMA treatment the ability of GST-Cterm to pull down AFAP-110 from cell lysates
decreases in time-dependent manner, and 6 hour treatment of cells co-expressing AFAP1105Y and active Src with PKC inhibitor bisindolylmaleimide restores the ability of GSTCterm to affinity absorb AFAP-1105Y from cell lysates (Baisden and Flynn, unpublished
data).
AFAP-110 has an intrinsic ability to remodel actin filaments as its leucine zipper
mutant over expression causes actin filament disruption in cultured cells. This ability
depends upon conformational changes in this protein, which affect its multimerization
status. AFAP-110 is hyperphosphorylated in Src transformed cells, not only on tyrosine
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but also on serine and threonine residues (124). Recent data indicates that
serine/threonine and not tyrosine phosphorylation of AFAP-110 is responsible for
changes in its self-association (Baisden et al, in preparation). AFAP-110 is a substrate
for PKC in vitro and serine/threonine phosphorylated in response to PKC activation in
vivo (Qian et al, accepted). Non-phosphorylated AFAP-110 cross-links actin filaments
whereas in response to PKC phosphorylation in vitro it bundles them (Qian et al,
accepted). Serine/threonine phosphorylation of AFAP-110 alters its function by induction
of AFAP-110 transition from actin-filament cross-linking to bundling protein. The
change in AFAP-110 function occurs in response to phosphorylation-dependent alteration
in its conformation and therefore the ability to self-associate. Recent evidence indicates
that the site for PKC phosphorylation that mediates this change exists in the
serine/threonine kinase interaction domain of AFAP-110 (125)(Cherezova and Flynn,
unpublished observation). PKC activation induces motility structure formation such as
lamellipodia and filopodia along with disappearance of actin stress fibers. Inside of
lamellipodia, actin exists as a network of bundles. AFAP-110 therefore may be involved
in PKC-dependent motility structure formation; upon phosphorylation by PKC AFAP110 may act as a protein mediating formation of a meshwork of short actin bundles
forming a skeleton of growing lamellipodia.
AFAP-110 therefore is a cellular adaptor protein regulated by serine/threonine
phosphorylation. Recent data suggest that PKC dependent phosphorylation influences
AFAP-110 self-association mode and actin filament cross-linking properties. Therefore it
becomes important to identify AFAP-110 phosphorylation sites playing a crucial role in
regulation of its function. The strategy and progress in identification of AFAP-110
functional phosphorylation sites are described in chapter two of this thesis.
AFAP-110 also contains several sequences that may enable its association with
another adaptor protein described above, 14-3-3. 14-3-3 proteins are known to act as
cellular scaffolds bringing signaling proteins into complexes, so if 14-3-3 interacts with
AFAP-110 it could bring AFAP-110 into proximity with kinases PKC and Raf and
possibly with other 14-3-3 numerous binding partners. Due to their dimeric nature 14-3-3
proteins are known to act as allosteric regulators, binding to different parts of the same
protein. As AFAP-110 contains more than one potential 14-3-3 binding sequence it is
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likely that 14-3-3 may regulate AFAP-110 conformation in response to cellular signals.
Chapter three of this thesis describes a strategy and data for determining whether 14-3-3
is a binding partner for AFAP-110.
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Chapter 2

Determining the effects of phosphorylation on
AFAP-110 function.
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I. Introduction:
AFAP-110

was

identified

as

a

phosphotyrosine

protein

that

co-

immunoprecipitates with active Src in vSrc-transformed cells (1). Some time later it was
discovered that AFAP-110 forms a stable complex with Src and also is phosphorylated
by this tyrosine kinase in in vitro kinase assay (2). Avian form of AFAP-110 was cloned
in 1993 (3). Immunofluorescence analysis demonstrated that in cultured cells AFAP-110
co localizes with actin stress fibers as well as with cortical actin matrix. In Srctransformed cells, which have disassembled actin filaments, AFAP-110 co-localizes with
actin rosettes or podosomes as well as with the actin underlying dynamic motility
structures at the leading edge of the cell such as lamellipodia, filopodia, and membrane
ruffles (3).
The domain structure of AFAP-110 indicates that this protein may be positioned
to modulate the effects of signaling proteins upon actin cytoskeleton (figure 1). AFAP110 contains several modular domains that mediate its interactions with such signaling
proteins as Src and PKC. AFAP-110 forms a stable complex with Src via SH2 and SH3
interactions (4;5); it associates with PKC via amino-terminal PH domain (Baisden and
Flynn, unpublished data). At the carboxy terminus of AFAP-110 there are also two actin
binding modules, which are responsible for direct interactions of AFAP-110 with actin
cytoskeleton (6). AFAP-110 possesses the ability to multimerize via carboxy-terminal
leucine zipper motif, although the multimerization is not achieved via classical leucine
zipper interactions. In normal cells AFAP-110 exists in a form of multimeric complexes,
which range from dimers to hexamers; even larger complexes were observed (7).
Deletion of carboxy terminal leucine zipper motif results in ability of AFAP-110 to
disassemble actin filaments into rosette-like structures similar to those, which are seen in
cells transformed by Src (6;6). AFAP-110, therefore, possesses an intrinsic ability to
rearrange actin cytoskeleton.
Recent experiments indicate that AFAP-110 function may be regulated by
phosphorylation. Even as early as 1991 it was known that in Src transformed cells AFAP110 is hyperphosphorylated not only on tyrosine, but also on serine and threonine
residues (4). That suggested a possibility of Src activating one or several serine/threonine
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kinases responsible for phosphorylation of AFAP-110. One possible candidate of
serine/threonine kinase that acts downstream of active Src is protein kinase C. Protein
kinase C family of serine/threonine kinases are well known modulators of cell growth,
cell motility and differentiation, also implicated into development and progression of
certain cancers (8) . PKC superfamily is divided into three subgroups based on their
structure and the nature of activators: conventional, novel and atypical PKC subfamilies.
Conventional PKCs are activated by PS, DAG and calcium ions; novel PKCs are
activated by PS, and DAG but not calcium; atypical PKCs are activated by PS, but
neither DAG nor calcium (9). DAG pharmacological analogs phorbol esters, for example
PMA, can also be used to activate conventional and novel PKC isoforms (10). PKCα is
known to be activated downstream of active Src (11), therefore it has been important to
test whether AFAP-110 would be a substrate and/or binding partner for this
serine/threonine kinase.
It has been determined in recent years that AFAP-110 is a substrate for PKCα in
vitro, as well as is phosphorylated in PKC-dependent manner in cultured cells. Several
PKC isoforms, including PKCα are able to associate with AFAP-110 via its amino
terminal PH domain (Baisden and Flynn, unpublished data). It was also discovered that
PKC-dependent serine/threonine phosphorylation alters AFAP-110 conformation, which
in turn results in alterations in AFAP-110 self-association. Phosphorylation by PKCα in
vitro enhances actin cross-linking ability of recombinant AFAP-110 (Qian et al, 2002).
Electron microscopy demonstrates that non-phosphorylated AFAP-110 cross-links actin
filament into a loose meshwork of interconnecting cables, whereas PKC-phosphorylated
AFAP-110 arranges actin filaments into a more organized network of short bundles (Qian
et al, 2002). Cumulatively, these data indicate that PKC-dependent phosphorylation
influences AFAP-110 ability to self-associate and cross-link actin filaments. Therefore,
it becomes important to identify phosphorylation sites within AFAP-110 structure that
are responsible for serine/threonine phosphorylation-induced changes in AFAP-110
structure and function.
In order to determine the identity of functional phosphorylation sites within
AFAP-110 structure we performed phosphotryptic analysis of recombinant AFAP-110
phosphorylated in in vitro PKC kinase assay as well as that of AFAP-110 derived from
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cultured cells either treated with PKC stimulator PMA or co-expressing active form of
Src (Src527F). Phosphotryptic mapping analysis demonstrated that PKCα phosphorylates
AFAP-110 on multiple residues as well as confirmed previous data that AFAP-110 is a
substrate for PKCα in vitro. Deletional mutageneses in conjunction with confocal actin
filament cross-linking assays were employed to determine which regions of AFAP-110
are most likely to contain functional phosphorylation sites. These experiments indicated
that the candidate sites are localized to the region encompassed by amino acids 249-294
of Serine Threonine Kinase Interaction (STK) region. Site directed mutagenesis of
putative PKC phosphorylation sites is being employed to alter the candidate serine for
alanine residues. More experiments are necessary to determine whether the serine
residues within amino acids 249-294 of STK region are the functional phosphorylation
sites that regulate AFAP-110 self-association and actin cross-linking properties.
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II. Materials and methods.
Reagents: DMEM, BME, PMA, bisindolylmaleimide, phosphatidylserine, and
diolein were purchased from Sigma.

Recombinant PKCα was purchased from

Calbiochem. Recombinant pp60c-Src was supplied by Upstate Biotechnology.

Anti-

AFAP-110 antibodies 4C3 and F1 were generated as previously described (3;12). AntiGST antibody was supplied by Santa Cruz Biotechnology. Gluthathione sepharose beads
and PreScission protease were from

Amersham Pharmacia Biotech. CalPhos

mammalian transfection kit was from Clontech. Lipofectamine 2000 transfection kit and
PCR Super Mix High Fidelity kit were from Gibco. Quick Change PCR mutagenesis kit
was supplied by Stratagene. General actin buffer BSA01, actin polymerization buffer
BSA02, ATP, rhodamine-phalloidin, and rabbit non-muscle actin were supplied by
Cytoskeleton. GelCode Blue Stain Reagent was from Pierce.
Cell Culture: Cos-7 cells were maintained in Dulbecco’s Modified Eagle’s
Medium (DMEM) supplemented with 5% Fetal Calf Serum, 2mM glutamine and 1%
penicillin/streptomycin.
Expression vectors: pCMV/AFAP-110 and pCMV/AFAP-110/Src527F were
described in (5;13). pGEX-6p-1-AFAP-110 were described by Qian et al, 2000 (6).
Primers for deletional mutagenesis: AFAP-110∆62-152 5′ primer was
GCAGGTACCTGCTGGCAGGCTGTTG;

and

the

3′

primer

AFAP-110∆PH1

ATCGGTACCGATGCCAAAATTTGTGCC.

the

AAGGGTACCCTTCACCAGATCCATAGAG;

5′

reverse

AFAP-110∆STK

GCTGGTACCAGCAACTGTACGGGCAC.

and

TGCGGTACCGCACACATCTTTTATAACC;

the

AFAP-110∆PH2

GAAGGTACCTTCTTCAGCTGACGAGG;

and

the

5′

5′

reverse

ATAGGTACCTATGACTATATCGATGTGG.

AFAP-110∆249-294

TGCGGTACCGCACACATCTTTTATAACC;

and

ATCGGTACCGATGTTCCAACATGTGG;
ACAGGTACCTGTGGTGATGCCATTTTCC.
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the

the

5′

was
was

primer

was

primer

was

primer

was

primer

was

primer

was

primer

was

5′

primer

was

reverse

primer

was

reverse

AFAP-110∆295-346
and

primer

reverse

ATCGGTACCGATGTTCCAACATGTGG.

CACGGTACCGTGTGCAACGGAAAAG.

primer

was

AFAP-110∆249-295

5′

primer

was

TACGGTACCGTACACAAGACAGAGCTG; and the reverse primer was 3′ primer used
in creating AFAP-110∆249-294 mutant. AFAP-110 ∆ 266-294 5′ primer was the same as for
AFAP-110∆249-294

5′

primer;

and

the

3′

primer

was

CCAGGTACCTGGAGAACTAGACAATGG.
Deletional

mutagenesis:

pGEX-6p-1-AFAP-110∆62-152,

pGEX-6p-1-AFAP-

110∆PH1, pGEX-6p-1-AFAP-110∆STK, pGEX-6p-1-AFAP-110∆PH2, pGEX-6p-1-AFAP110∆249-294, pGEX-6p-1-AFAP-110∆295-346, pGEX-6p-1-AFAP-110∆249-265, pGEX-6p-1AFAP-110∆266-294 were created by PCR amplification with PCR Super mix High Fidelity
kit using primers with engineered KpnI restriction site described above (KpnI site
underlined). Briefly, 45 µl of PCR High Fidelity Mix was mixed with 100 ng of template
DNA (pGex-6p-1-110) and primers were added to 200nM final concentration; final
volume of reaction was 50 µl. The reactions were overlaid with 30 µl mineral oil and
subjected to PCR overnight. PCR machine was programmed according to PCR Super mix
High Fidelity supplier recommendations, so the reaction was carried out at 94 degrees for
30 seconds, followed by 35 cycles of 94 degrees for 30 seconds, 55 degrees for 30
seconds, and 68 degrees for 7 minutes and 30 seconds. PCR products were digested with
10 units of KpnI for 2 hours and purified on 0.8% agarose gel. The DNA was then
transferred by electrophoresis to DEAE membrane, which was subjected to 45-minute
incubation in 350µl, and consequently 15-minute incubation in 150 µl of High Salt
DEAE membrane buffer (10.0 ml 5M NaCl, 10.0 ml 0.5M EDTA, 1 ml 1M Tris, 39ml
MilliQ water) at 65 degrees and then to place DNA into solution. DNA-containing High
Salt DEAE membrane buffer 350 µl and 150 µl portions were combined, and DNA was
ethanol precipitated, vacuum dried, and the pellet was dissolved in 16 µl of autoclaved
MilliQ water. 2 µl of 10X ligation buffer (Roche) and 2 units of T4 DNA ligase (Roche)
were mixed with the DNA, and the reaction was allowed to proceed at 16 degrees for 16
hours. 3 µl of ligation reactions were used to transform E. coli DH5α competent cells by
electroporation. Bacterial cells were then incubated in 1 ml LB Broth at 37 degrees with
shaking for 1 hour; 20 µl and 200 µl aliquots were plated on 1X Ampicillin LB plates.
Cultures from several colonies were inoculated for mini-scale DNA preparation, and the
extracted DNA was screened by restriction mapping to determine which colonies contain
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pGEX-6P-1-110 plasmid bearing desired deletion.
Site

directed

mutagenesis.

pCMV/AFAP-110S186,210A,

pCMV/AFAP-

110S276,277A, pCMV/AFAP-110S281,282A, and pCMV/AFAP-110S276,277,281,282A were created
by PCR-based site-directed mutagenesis using primers with nucleotide mismatches
containing desired mutation. Briefly, 20 ng of pCMV/AFAP-110 template was mixed
with 5 ml of 10X reaction buffer (Stratagene), 125 ng of each primer, 1 ul of 10 mM
dNTP mix (Stratagene), and 2.5 units of Pfu Turbo DNA polymeraze. The volume of
PCR mix was brought to 50 ml with HPLC grade autoclaved water. The reactions were
overlaid with 30 ml of mineral oil. The ractions were carried out at 95 degrees for 30
seconds, and 18 cycles of 95 degrees at 30 seconds, 55 degrees for 1 minute, and 68
degress for 15 minutes. The reactions were than incubated at 37 degrees for 1 hour with
10 units of DpnI restriction enzyme (Roche) to digest the template. 1 ul of each PCR
reaction was added to 50 ul of Epicurian coli XL-1 Blue supercompetent cells and
incubated on ice for 30 minutes. The transformation reactions were heat-pulsed for 45
seconds at 42 degrees, and placed on ice for 2 minutes. After that 0.5 ml of NZY-Broth (5
grams of NZ amine, 2.5 grams of yeast extract, 2.5 grams of NaCl were diluted in 500 ml
of MilliQ water and autoclaved. 6.25 ml of 1 M MgCl2 and 6.25 ml of 1 M MgSO4 and 5
ml of a 2M filter-sterilized glucose solution were added to the autoclaved broth, and
filter-sterilized) preheated to 42 degrees was added to each transformation reaction, and
the reactions were incubated at 37 degrees with shaking for 1 hour. After that the
reactions were plated onto 2X Ampicillin LB plates. Cultures from several colonies were
inoculated for mini-scale DNA preparation, and the extracted DNA was screened either
by restriction mapping or DNA sequencing to determine which colonies contain
pCMV/110 plasmid vector bearing desired substitution.
GST-fusion protein induction: Wild type AFAP-110 or mutants in pGEX-6p-1
vector were put into E. coli DH5α cells. A starter culture was grown at 37 degrees
overnight in 50 µg/ml ampicillin LB-Broth media. Starter culture was diluted with fresh
50 µg/ml ampicillin LB broth in a 1:20 ratio and incubated at 37 degrees with shaking for
1 hour. IPTG was added to bacterial culture to 0.5 mM concentration. Cultures were
incubated for 5 hours at 30 degrees with shaking. Bacterial pellets were harvested by
centrifugation at 6000 rpm for 5 minutes and resuspended in 1%TritonX MT-PBS (150
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mM NaCl, 16 mM Na2HPO4, 4 mM NaH2PO4, 1% Triton X). Bacterial cell walls were
disrupted by sonication, centrifuged at 10000 rpm to separate cell wall debris from lysate.
Lysate-containing supernatant was collected and stored at –80-degree freezer until
needed.
Immobilization of fusion protein on gluthathione sepharose beads:
Gluthathione sepharose beads were washed into 1% Triton X MT-PBS. GST fusion
protein lysates were mixed with bead slurry and incubated for 1 hour at 4 degrees with
shaking. After that the bead-fusion protein complexes were washed in 1% Triton X MTPBS and stored at 4 degree refrigerator for future use.
Cleavage of proteins from GST - gluthathione sepharose beads complexes:
Bead-GST-fusion protein complexes were washed into PreScission protease cleavage
buffer (50mM Tris, 150 mM NaCl, 1 mM EDTA, 1mM DTT). For each ml of washed
Gluthathione Sepharose bed volume 80 units of PreScission protease were mixed with
PreScission protease cleavage buffer, and the mixture was added to the beads. Cleavage
was allowed to proceed for 16 hours at 4 degrees. Protein-containing supernatant was
collected and stored at –20-degree freezer for future use.
Dialysis and concentration of recombinant proteins: Recombinant proteins in
PreScission cleavage buffer were placed into dialysis membrane bags and incubated for
24 hours in a dialysis buffer (5 mM Tris, 0.2 µM CaCl2) with gentle stirring at 4 degrees.
Dialyzed proteins were concentrated using Microcon concentration tubes. Concentration
proceeded by sequential centrifugation of 500 µl aliquots of dialysed protein samples at
11000 rpm for 10 minutes. The concentrated protein solution was collected by
centrifugation at 2000 rpm for 5 minutes. The yield was determined by resolving 1 µl
aliquots of recombinant protein on a 8% SDS-PAGE with BSA molecular weight
standards followed by staining of gel with GelCode Blue Stain Reagent.
In vitro phosphotryptic mapping: GST-AFAP-110 bound to gluthathione
sepharose beads was washed into PKC assay buffer (20 mM Tris, pH 7.5, 5 mM MgCl2,
0.2 mM CaCl2, 20 µg/ml phosphatidylserine, 2µg/ml diolein). 5µg of recombinant PKCα
and 200 µCi 32P-γ-ATP were added per 1 ml of beads with recombinant protein into the
reaction tube, and in-vitro phosphorylation was allowed to proceed for 2 hours at 30degree incubator with shaking. Gluthathione sepharose bead slurry was washed into pre-
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scission protease cleavage buffer, 80 units of PreScission protease were added per ml of
washed Gluthathione Sepharose bed volume, and cleavage proceeded for 16 hours at 4
degrees with shaking. Supernatant, containing
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P-γ phosphorylated protein, was

collected, and protein was precipitated with 250 µl ice cold TCA using 20 µg of RNase A
as a carrier protein. The pellet was washed with ethanol, air dried, resuspended in 100 µl
of 2XLSB, boiled for 5 minutes and subjected to 8 % SDS-PAGE. SDS-PAGE with 32P-γ
phosphorylated protein in it was exposed to film and radioactive band was excised.
Radioactively labeled protein was eluted out of acrylamide with two changes of 500 µl
50mM NH4HCO3 with 50 µl 2ME and 10 µl 10 % SDS. Radiolabeled protein was TCA
precipitated as described above. Immobilized trypsin was washed into 50mM NH4HCO3
buffer and mixed with TCA precipitated radiolabeled protein. Tryptic digestion was
allowed to proceed in 37-degree incubator for 16 hours. Phosphotryptic peptide
containing supernatant was collected and lyophilized. The pellet was washed and
lyophilized twice in milliQ water, resuspended in 6 µl buffer pH=1.9 (50 ml 88% formic
acid, 156 ml glacial acetic acid, 1794 ml MilliQ water) and loaded on TLC plates.
Samples were run via electrophoresis for 1 hour at 1kVolts in a pH=1.9 buffer in first
dimension, then for 16 hours in a chromatography buffer optimized for phosphopeptides
(750 ml n-butanol, 607 ml pyridine, 150 ml glacial acetic acid, 600 ml MilliQ water) in
the second dimension using the HTLE7000 system, according to manufacturers
instructions. TLC plates with two-dimentionally separated phosphotryptic peptides were
exposed to phosphorimager cassettes for at least 16 hours. Radioactive spots
representative of phosphotryptic peptides were analyzed using phosphorimager.
In vivo phosphotryptic mapping: For PMA treatment, Cos-7 cells were grown
to 60% confluence in 100 mm culture dishes, transiently transfected with pCMV/AFAP110 or pCMV/AFAP-110/Src527F using CalPhos transfection kit, serum starved overnight
in the presence of 2.5 mCi of radioactive orthophosphate, then stimulated with 100 nM
PMA for 1 hour. To determine effects of activated Src on AFAP-110, Cos-7 cells were
grown to 60% confluence in 100 mm culture dishes, transiently transfected with
pCMV/AFAP-110/Src527F plasmid

and

labeled

with

2.5

mCi

of

radioactive

orthophosphate. 60-66 hours after transfection cells were washed twice with PBS and
lysed with 1 ml RIPA lysis buffer (1% NP-40, 0.25 % deoxycholate, 150mM NaCl,
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50mM Tris, pH=7.5) supplemented with protease and phosphatases inhibitors (50 µg/µl
aprotinin, 2mM Sodium Vanadate, 2mM PMSF, 2 mM EGTA, 10 µg/ml Leupeptin). 2
µl monoclonal antibody 4C3 was used to immunoprecipitate AFAP-110 from the Cos-7
lysate. 30 µl of protein A agarose was used as a secondary antibody to pull down 4C3AFAP-110 complexes. Immunoprecipitates were resuspended in 2X LSB, boiled and
subjected to 8% SDS-PAGE. From this step the experiment proceeded as described in in
vitro phosphotryptic mapping protocol.
In vitro PKC kinase assay: 0.4 µg of recombinant protein (AFAP-110 or mutant)
was mixed with 0.2 µg of human recombinant PKCα in the presence of 2.5 nanomoles
ATP in a PKC assay buffer (20 mM Tris, pH 7.5, 5 mM MgCl2, 0.2 mM CaCl2, 20 µg/ml
phosphatidylserine, 2µg/ml diolein). The reactions were incubated at 30 degrees for 30
minutes.
In vitro Src kinase assay for in vitro phosphotryptic mapping: GST-AFAP110 bound to gluthathione sepharose beads was washed into Src kinase buffer (100mM
Tris-HCl, pH=7.2, 125 mM MgCl2, 25mM MnCl2, 2mM EGTA, 0.25mM sodium
orthovanadate, 2mM dithiothreitol). 30 units (10 µl) of recombinant Src kinase and 200
µCi of
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P-γ-ATP were added to the reaction tube already containing gluthathione

sepharose beads with GST-AFAP-110 in Src kinase buffer. The phosphorylation reaction
was allowed to proceed for 2 hours at 30 degrees with shaking.
Confocal microscopy actin cross-linking assays: Rabbit nonmuscle G actin was
resuspended in general actin buffer BSA01 to concentration 50 ug/ul (5mM Tris, pH=8.0;
0.2mM CaCl2), snap-frozen in liquid nitrogen and kept at –80-degree freezer until
needed. 2µM F-actin stock was prepared from G-actin in 5mM Tris-HCl pH 8.0, 0.2mM
CaCl2, 0.5 mM DTT, 100mM MgCl2, and 50mM ATP at room temperature for 1 hour.
Then F-actin was labeled with rhodamine-phalloidin by incubating F-actin with 0.5 µg/µl
rhodamine-phalloidin in proportion 9:1 for 3 hours at 4 degrees. Rhodamine-phalloidinlabeled F-actin was mixed with recombinant AFAP-110 or AFAP-110 mutants, either
phosphorylated or non-phosphorylated by PKC in vitro, in 5mM MgCl2, 1mM EGTA,
2mM ATP, 50mM KCl at room temperature for 30 minutes. After the incubation,
reactions were placed on the glass slides, covered with coverslips, sealed and analyzed

42

under Zeiss LSM 510 confocal microscope.
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III. Results.
Previous data indicates that AFAP-110 is a substrate for PKC in vitro and is
phosphorylated on serine and threonine residues in vivo in response to treatment of
cultured cells with phorbol ester PMA or co-expression of active Src. Serine/threonine
phosphorylation alters AFAP-110 ability to self-associate and enhances its actin crosslinking capability (Baisden and Flynn, unpublished data; Qian et al, 2002, MBC).
Therefore it becomes important to identify AFAP-110 phosphorylation sites, which play
a pivotal role in regulation of AFAP-110 function.
We started to approach phosphorylation sites identification using phosphotrypticmapping analysis of recombinant AFAP-110 according to the protocol described by
Boyle and co-workers (14). Recombinant AFAP-110 was incubated with human
recombinant PKCα in vitro at a molar ratio of 20:1 substrate to enzyme in the presence of
radioactive ATP in PKCα kinase buffer containing co-factors for cPKC. Phosphorylated
AFAP-110 was then purified on 8% SDS-PAGE, eluted out of acrylamide and digested
with trypsin. Phosphotryptic peptides were subjected to two-dimensional separation on
TLC plates, which were then analyzed using phosphorimager.
Phosphotryptic mapping analysis of recombinant AFAP-110 revealed that 14
phosphotryptic fragments are generated in response to AFAP-110 phosphorylation by
PKCα in vitro. This experiment confirmed that AFAP-110 is a substrate for PKCα in
vitro and also demonstrated that PKCα phosphorylates AFAP-110 on multiple residues.
Figure 2A.
In order to determine whether any of these fragments are generated in response to
PKC activation in vivo, Cos-1 cells transiently expressing AFAP-110 were radiolabeled
with
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P-orthophosphate and subjected to 1-hour treatment with 100nM phorbol-12-

myristate-13-acetate (PMA) to activate PMA-inducible PKC isoforms. Also, Cos-1 cells
were transiently co-transfected with AFAP-110 and active form of non-receptor tyrosine
kinase Src (Src527F), which is known to activate PKCα (11); these cells were also
radiolabeled with
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P-orthophosphate. AFAP-110 was pulled down from these cells by

immunoprecipitation with anti-AFAP-110 antibody 4C3, gel purified, and digested with
trypsin. Phosphotryptic peptides were subjected to two-dimensional separation on TLC
plates (Figure 2, B and C). Only six phosphotryptic fragments appear on both in vivo
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maps (Figure 2, B and C), four of which are common to both in vivo maps (indicated by
arrowheads). Comparison of the three maps (Figure 2, A, B and C) reveals the presence
of two common fragments among them (indicated by black arrowheads). Both in vivo
maps (B and C) contain two phosphotryptic fragments (indicated by white arrowheads),
which are not present on in vitro map (A). These fragments may represent peptides that
are actually present on in vitro map, but positioned differently on in vivo maps due to in
vivo posttranslational modifications other than phosphorylation, which affect their
molecular weight and/or hydrophobicity. Alternatively, these fragments may be
generated in response to phosphorylation of AFAP-110 by PKC or other PMA activated
serine/threonine kinases on residues, which are not phosphorylated by recombinant
PKCα in vitro. One more explanation of the differences among fragments from in vitro
and in vivo maps could be that in vivo derived peptides may also be phosphorylated on
tyrosine residues, especially in cells co-expressing active form of Src, which would
therefore result in change of their mobility in both dimensions on TLC plates. Neither
peptide on maps B nor C represents a phosphotryptic fragment phosphorylated only on
tyrosine residues, as no phosphotryptic peptide on maps B and C migrates in the same
manner as the AFAP-110 tryptic fragment(s) phosphorylated with recombinant Src in
vitro (Figure 2 D).
Previous data of Qian et al (Qian et al, 2002) indicates that AFAP-110 is an actin
cross-linking protein, and that phosphorylation by PKC enhances actin cross-linking
properties of AFAP-110. Qian et al used confocal microscopy actin filament crosslinking assays as well as AFAP-110 and actin filament low speed co-sedimentation
assays to obtain their data. For confocal actin filament cross-linking assay filamentous
actin was prepared in vitro and labeled with rhodamine-phalloidin, and then it was
incubated either alone or with non-phosphorylated or phosphorylated AFAP-110.
According to Qian et al, in the absence of actin cross-linking protein actin appears
uniformly fluorescent, whereas in the presence of non-phosphorylated AFAP-110 actin
filament become organized into a pattern of interconnecting fluorescent cables. In the
presence of PKC phosphorylated AFAP-110 actin appears in a form of large bright
aggregates of fluorescence, which are representative of tightly organized actin filaments,
with a dark spaces among them (Qian et al, 2002). These data along with the data from
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actin pelleting assays (Qian et al, 2002) indicates actin cross-linking properties of AFAP110 are regulated by serine/threonine phosphorylation and accentuates the importance of
determining the identity of these sites.
PKC consensus site is represented by serine or threonine residue in a position 0
with a basic amino asid(s) lysine or arginine in a position –4, -3, -2 and/or +2, +3, +4
(15). AFAP-110 contains over twenty putative PKC phosphorylation sites (Table 1).
Table 1
N

Amino
acid
number

1

10 - 25

2

38 - 42

3

53 -104

4

186 - 188

LLCYK

SSK

5

209 - 211

…DCSITYIPK

DSK

6

246 - 268

VIK

7

275 - 299

TELEKK

8

307 - 309

RKK

9

319 - 322

GTVTK

10

405 - 410

11

485 - 512

12

515 - 526

13

642 - 645

Preceding
fragment

AFAP-110 phosphotryptic fragment containing
putative PKC site(s)
LFLELLDHEYLTSTVR

…NILLR

IQSSK
………IPQQWLPPDNGPPPLPTSSLPEGYYEEAVPVSPGK

DVCSNCTGTVDSDGPLSSSPVHK
LSSERPSSDGEGAVENGITTVCNGK
SSK
VTGK
HPLTFR

VISTNPYR

GSTANGYACPSGMALHYDDVPCINGSFK
KPPATANGITGK

LTEVK

ESLK

Therefore it would not be worthwhile to employ site directed mutagenesis before
it has been determined which region of AFAP-110 is most likely to contain functional
sites of phosphorylation. In order to determine which regions of AFAP-110 are most
likely to contain functional AFAP-110 phosphorylation sites responsible for
phosphorylation-dependent change in actin cross-linking ability of this protein PCRbased deletional mutagenesis was performed. GST-tagged AFAP-110 mutants missing
amino acids 62-152 (SH3 binding, potential WW, SH2 binding motifs), 153-248
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(PH1domain), 249-346 (Serine threonine kinase interaction region), and 347-450 (PH2
domain) were created (Figure 3).
GST-tagged recombinant AFAP-110 bearing each of these deletions was made in
bacteria, purified on gluthathione sepharose beads, and digested from gluthathione
sepharose bound GST portion with preScission protease. AFAP-110 was then dialyzed
and concentrated on microcon concentrating tubes. Full-length AFAP-110 and deletion
mutants were phosphorylated by recombinant PKCα in vitro, and incubated with
rhodamine-phalloidin labeled filamentous actin. The reactions were analyzed by confocal
microscopy actin cross-linking assays developed by Qian and colleagues (Qian et al,
2002). In the presence of non-phosphorylated AFAP-110 actin filaments are organized
into a network of interconnecting fluorescent filaments (Figure 4 A and B), whereas
confocal microscopy image of actin filaments incubated with PKC-phosphorylated
AFAP-110 demonstrates appearance of large bright aggregates of fluorescence
representative of tighter cross-linked actin filaments (figure 4 C and D). These data
repeated the results of Qian et al (Qian et al, 2002) indicating that phosphorylated AFAP110 cross-links actin filaments much more efficiently than non-phosphorylated. Confocal
actin cross-linking assay therefore may be used as an in vitro test for AFAP-110 function.
Confocal analysis of PKCα-phosphorylated versus non-phosphorylated AFAP-110
mutants demonstrates that three out of four deletions alter actin cross-linking properties
of AFAP-110. When AFAP-110 mutant, missing SH3 binding motif, potential WW motif
and amino terminal SH2 binding motif (AFAP-110∆62-152), phosphorylated by PKCα in
vitro is incubated with rhodamine-labeled filamentous actin, most of the actin filaments
appear in a form of network, with few actin aggregates scattered all over slide area
(Figure 5).
Deletion of SH3 binding, potential WW, and SH2 binding regions of AFAP-110
therefore reduces PKC ability to enhance actin cross-linking properties of AFAP-110, but
does not eliminate it completely. AFAP-110 mutant missing amino terminal PH domain
(AFAP-110∆PH1) loses the ability to cross-link actin efficiently in response to PKCα
phosphorylation (Figure 6 C and D), but the incubation of actin filaments with nonphosphorylated PH1 deletion mutant results in appearance of bright actin aggregates
indicative of efficient actin filament cross-linking by this construct (Figure 6 A and B).
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AFAP-110∆PH1 therefore can cross-link actin filaments efficiently in the absence of
phosphorylation, in the same manner as PKC phosphorylated full length AFAP-110,
however, in response to phosphorylation it can only cross-link filamentous actin into a
loose network similar to non-phosphorylated full length AFAP-110.
Rhodamine-labeled actin filaments incubated with phosphorylated AFAP-110
mutant missing serine/threonine kinase interaction region

(AFAP-110∆STK) appear

exactly the same was as F-actin incubated with non-phosphorylated mutant; they are
arranged into network of fluorescent fibrils with no bright actin aggregates at all (Figure
7). Phosphorylation by PKCα fails to enhance actin cross-linking ability of this deletion
mutant. The data presented in Figure 7 indicate that the integrity of STK region is
important for PKC-phosphorylation-dependent regulation of AFAP-110 function. There
are two possible hypotheses as to why AFAP-110∆STK fails to cross-link filamentous actin
into a tighter aggregates in response to phosphorylation by PKCα. One of them is that
AFAP-110 may undergo a conformational change as a result of deletion of amino acids
249-346 in a way that this protein can no longer associate with and/or be phosphorylated
by PKCα. Another one is that STK region of AFAP-110 contains functional
phosphorylation sites within its structure, and it is their disappearance that results in
inability of PKCα to alter AFAP-110∆STK actin filament cross-linking properties.
AFAP-110 mutant missing carboxy terminal PH domain (AFAP-110∆PH2) behaves
in the same manner as the full length AFAP-110 (Figure 8). Non-phosphorylated AFAP110∆PH2 cross-links actin filaments into loosely interconnecting actin cables (Figure 8 A).
Phosphorylation by PKCα enhances the ability of AFAP-110∆PH2 mutant to efficiently
cross-link actin filaments into tighter aggregates (Figure 8 B). Deletion of carboxy
terminal PH domain does not seem to have any effect on PKC-phosphorylationdependent ability of AFAP-110 to cross-link actin filaments, and therefore PH2 domain
is hardly likely to contain functional phosphorylation sites.
AFAP-110∆STK completely loses the ability to efficiently cross-link actin in
response to phosphorylation by PKCα. Therefore STK region of AFAP-110 may contain
functional phosphorylation sites within its structure. There are several putative PKCα
target sites within this region (Table 1). Before we attempt to change them all at once,
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one by one or in combinations by site-directed mutagenesis, we decided to narrow down
the area even further and create two more deletion mutants.
In attempt to discover whether it is a matter of phosphorylation sites, two more
deletion mutants were created: GST-tagged AFAP-110 missing amino acids 249-294
(first half of STK region) and amino acids 295-346 (second half of STK region) (Figure
9). These mutants were also expressed in bacterial cells, purified as described above,
phosphorylated by PKCα in vitro and incubated with rhodamine-phalloidin labeled actin
filaments and analyzed using confocal microscope.
Actin filaments incubated with PKC-phosphorylated AFAP-110∆249-294 appear as
a network of fluorescent cables, same as F-actin incubated with non-phosphorylated
AFAP-110∆249-294 mutant or wild type (Figure 10).
PKC-phosphorylated AFAP-110∆295-346 is able to cross-link actin into a large
bright fluorescent aggregates in a same manner as PKC phosphorylated full length
AFAP-110, whereas non-phosphorylated AFAP-110∆295-346 behaves exactly as the full
length AFAP-110 (Figure 11). These data suggest that the integrity if the amino-terminal
half of STK region is the most important for PKC-dependent regulation of AFAP-110
actin cross-linking ability. The first half of STK region therefore may contain the
phosphorylation sites crucial for the regulation of AFAP-110 function by serine/threonine
phosphorylation. In an attempt to further narrow down the AFAP-110 region containing
functional serine/threonine phosphorylation sites, two more deletion mutants were
created by PCR-based deletional mutagenesis.
These AFAP-110 mutants miss either amino acids 249-265 (first quarter of STK
region) or amino acids 266-294 (second quarter of STK region) (Figure 12). GST-tagged
AFAP-110∆249-265 and AFAP-110∆266-294 were expressed in bacterial cells, purified,
cleaved off GST portion, dialyzed, concentrated and phosphorylated by PKCα in vitro.
Rhodamine labeled actin filaments were incubated with PKC phosphorylated versus nonphosphorylated these mutants. Results of this experiment are shown in figures 13 and 14.
Non-phosphorylated AFAP-110∆249-265 and AFAP-110∆266-294 cross-link actin in
the same manner as non-phosphorylated full length AFAP-110 (Figures 13 and 14, panels
A). Actin filaments incubated with phosphorylated forms of these mutants mostly
organized into network of fluorescent bundles with very few bright aggregates of more
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tightly cross-linked actin (Figure 13 and 14, panels B). There are fewer of these
aggregates in case of PKC-phosphorylated AFAP-110∆266-294 (Figure 14 B) rather than in
case of PKC-phosphorylated AFAP-110∆249-265 (Figure 13 B). These data suggest that
more important functional phosphorylation sites are localized to amino acids 266-294
within STK region. Incomplete loss of AFAP-110∆266-294 to efficiently cross link actin
upon PKC phosphorylation suggests that multiple phosphorylation sites may be
responsible for this, and some of them may be localized to amino acids 249-265. There
are four serine residues within second quarter of STK region – S276, 277, 281 and 282.
They all fall into definition of PKC phosphorylation sites. They will be mutated to
alanine residues in pairs or all at once, and various experiments will be performed to
determine whether these are the functional phosphorylation sites.
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IV. Discussion.
AFAP-110 is a multidomain adaptor protein, which was discovered as a Srcassociated tyrosine phosphorylated protein (2). AFAP-110 domain structure suggests that
this protein can be positioned to alter actin cytoskeleton in response to cellular signals.
Indeed, AFAP-110 binds Src directly via SH2- and SH3 binding motifs, and also
interacts with PKC via its amino-terminal PH domain; AFAP-110 has the ability to bind
actin directly via its carboxy-terminally located actin binding modules (16). AFAP-110
also has the ability to self-associate via leucine zipper interactions; gel filtration analysis
of cellular AFAP-110 demonstrated that in normal cells AFAP-110 is present mostly in
the form of large complexes like tetramers, pentamers or hexamers or even larger ones. In
response to co-expression with active Src it exists predominantly in a form of dimers (7).
AFAP-110 has an intrinsic ability to remodel actin cytoskeleton as the deletion of leucine
zipper motif enables this protein to cause disorganization of actin stress fibers into actin
rosettes similar to ones often seen in cells expressing active Src; AFAP-110∆lzip also
induces lamellipodia and filopodia formation (6). Previous data have shown that AFAP110 may be regulated by serine/threonine phosphorylation in response to activation of
cellular kinases Src and PKC.

AFAP-110 is a substrate for PKCα in vitro and is

phosphorylated in response to PKC activation in vivo (Baisden and Flynn, unpublished
data). Serine/threonine phosphorylation is thought to cause alterations in AFAP-110
conformation, which are responsible for changes in its multimerization status. Recently it
was determined that large multimeric complexes formed by non-phosphorylated AFAP110 are thought to cross-link actin filaments in a loose manner, promoting assembly of a
meshwork of cross-linked actin filaments, whereas AFAP-110 dimers formed by
serine/threonine phosphorylated protein arrange actin filaments into more dense
structures which can be described as a networks of short tight actin bundles (Qian et al,
accepted). Activation of cellular kinase PKC promotes actin stress fibers disassembly but
in the same time induces actin filament organization into a meshwork of cross-linked
short bundles, which act as a skeleton for lamellipodia. AFAP-110 is a protein that may
act as a PKC effector responsible for those changes, and its ability to rearrange actin is
regulated by serine/threonine phosphorylation. Therefore it became important to identify
phosphorylation sites within AFAP-110 structure that are responsible for changes in
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AFAP-110 conformation, self-association status and actin cross-linking ability of this
protein.
Fist of all, AFAP-110 was subjected to phosphotryptic mapping analysis.
Phosphotryptic map of in vitro PKC phosphorylated recombinant AFAP-110 reveals
presence of fourteen spots which indicate that PKC phosphorylates AFAP-110 on
multiple residues and also confirms data of Baisden and Flynn that AFAP-110 is a
substrate for PKC in vitro. Phosphotryptic maps of in-vivo derived AFAP-110 purified
from cultured cells either treated with PMA or co-expressed with active Src demonstrate
lesser number of phosphotryptic fragments but nonetheless confirm that AFAP-110 is
phosphorylated in vivo in PKC dependent manner. Each in vivo map reveals the presence
of six fragments total, four of which coincide between the two in vivo maps suggesting
that most of the fragments on in vivo map of AFAP-110 over expressed with active Src
are serine/threonine phosphorylated fragments. Two fragments (indicated by black
arrowheads on figure 2) are common between the in vivo maps and the recombinant
AFAP-110 phosphorylated by PKC in vitro map suggesting that those two fragments
must be phosphorylated by PKC in vivo. There are fragments present on in vivo
phosphotryptic maps, which are absent from in vitro phosphotryptic map; their different
mobility in both dimensions may be explained by the presence of posttranslational
modifications other than phosphorylation in AFAP-110 purified from mammalian cells
and/or by the fact that those fragments are phosphorylated on tyrosine residues as well.
Phosphotryptic mapping, although a useful technique, cannot provide us with an
answer which serine/threonine residues within AFAP-110 structure are phosphorylated in
response to PKC activation. When we analyze AFAP-110 amino acid sequence, we find
that AFAP-110 contains over twenty potential PKC phosphorylation sites (table 1). It
would not be rational to try to change all these serine or threonine residues one by one or
in combinations until we know which regions of AFAP-110 are most likely to contain
functional phosphorylation sites. In order to identify the region(s) of AFAP-110
containing functional serine/threonine phosphorylation sites we have decided to use
deletional mutagenesis in conjunction with an actin filament cross-linking assays as a test
for AFAP-110 function developed by Yong Qian (described in Qian et al, accepted).
At first, four deletion mutants missing either amino-terminally located SH3-
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binding, potential WW-binding and SH2- binding motifs, amino terminal PH domain,
STK region or carboxy-terminal PH domain were created and tested for the ability to
cross-link filamentous actin in response to PKC phosphorylation in vitro. AFAP-110
mutant missing amino-terminally located SH3- binding, potential WW-binding and SH2binding motifs (AFAP-110∆62-152) demonstrated a partial loss of ability to cross-link actin
efficiently in response to PKC phosphorylation in vitro, but not the complete inability to
cross-link actin filaments into the tight aggregates (figure 5), whereas AFAP-110 mutant
missing carboxy-terminal PH domain (AFAP-110∆PH2) behaved in the same manner as
the full length AFAP-110, displaying an increase in actin cross-linking ability upon
PKCα-phosphorylation. AFAP-110∆PH1 mutant on the other hand displayed a peculiar
behavior. In the absence of PKCα phosphorylation this mutant cross-linked actin
filaments as efficiently as PKCα phosphorylated wild type AFAP-110, whereas
phosphorylated AFAP-110∆PH1 could only loosely cross-link filamentous actin in a
manner resembling that of wild type non-phosphorylated AFAP-110, and did not bring
actin filaments into tight aggregates. This behavior of PH1 deletion mutant may be
explained by the fact that amino terminal PH domain participates in AFAP-110 selfassociation. PH1 is known to interact with carboxy terminal leucine zipper motif; these
interactions are thought to stabilize AFAP-110 multimerization (Qian et al, accepted).
Deletion of carboxy terminal leucine zipper motif results in ability of AFAP-110 to
efficiently cross-link actin without PKCα phosphorylation in confocal actin filament
cross-linking assays (Qian et al, accepted). It has been determined by Qian and
colleagues that full length AFAP-110 exists in a form of nanomers in actin buffer,
whereas AFAP-110 missing leucine zipper motif is found only in a form of trimers (Qian
et al, accepted). Therefore we hypothesize that deletion of amino terminal PH domain of
AFAP-110 results in a loss of an opposing binding site for leucine zipper motif, therefore
AFAP-110 may not have been able to form multimers larger than dimers or trimers, and
so the changed state of multimerization may have been responsible for the ability of
AFAP-110∆PH1 to cross-link actin filaments efficiently on its own. Surprisingly, PKCα
phosphorylation of AFAP-110∆PH1 mutant down-regulates its actin cross-linking ability.
We do not know why that occurs, it may be that phosphorylation of AFAP-110∆PH1
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mutant induces a conformational change in this protein so that it can no longer form
dimers or trimers, AFAP-110 may only exist in a form of monomers or conversely,
phosphorylation of this particular mutant may alter its conformation in a way that
formation of larger complexes becomes possible. Additional experiments are needed to
determine multimerization status of AFAP-110∆PH1 in PKCα-phosphorylated versus nonphosphorylated states.
AFAP-110∆STK mutant demonstrated a complete loss of PKCα- induced ability to
cross-link actin filaments efficiently into tight aggregates. This mutant, whether
phosphorylated or non-phosphorylated, could only loosely cross-link actin filaments in a
manner identical to that of non-phosphorylated wild type AFAP-110. There are two
possible explanations why this has happened: one of them is that STK region contains
pivotal PKC phosphorylation sites responsible for AFAP-110 regulation in response to
serine/threonine phosphorylation; another explanation may be that the deletion of STK
region caused a change in AFAP-110 conformation so AFAP-110∆STK mutant could no
longer associate with and/or be phosphorylated by PKCα. There is a strong indication
that AFAP-110 inability to efficiently cross-link actin in response to phosphorylation
occurs due to the first reason because STK region contains nine serine and threonine
residues which fall into definition of PKC consensus sites (table 1, fragments 6-9).
In order to narrow down the area of investigation further two more AFAP-110
deletion mutants were created - missing either first or second half of STK region, called
AFAP-110∆249-294 and AFAP-110∆295-346, missing six and three potential PKC
phosphorylation sites, respectively. Both mutants were tested in confocal in vitro actin
filament cross-linking assays to determine the effects of each deletion on the ability of
PKCα to enhance actin filament cross-linking properties of AFAP-110. AFAP-110∆249-294
behaved exactly as AFAP-110∆STK - in other words it failed completely to cross-link
filamentous actin efficiently in response to PKCα phosphorylation, whereas actin
filaments cross-linking ability of AFAP-110∆295-346 was enhanced in response to PKCα
phosphorylation in the same manner as in case of the full length AFAP-110. Therefore
we conclude that the amino terminal half of serine threonine kinase interaction domain of
AFAP-110 is the region the integrity of which is important for PKC-dependent regulation
of AFAP-110 function, and that the functional phosphorylation sites are most likely to
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reside within this region. There are six potential PKC phosphorylation sites within amino
acids 249-294; so in order to narrow down the area even further two more deletion
mutants were made- AFAP-110 missing either first quarter (AFAP-110∆249-265) or second
quarter (AFAP-110∆266-294) of STK region. These mutants were tested for their ability to
cross-link actin with or without PKCα phosphorylation in confocal actin cross-linking
assays. The results of the first experiment have shown that both mutants demonstrate
partial loss of ability to efficiently cross-link actin upon PKCα phosphorylation (figures
13 and 14). Confocal data is qualitative rather than quantitative, but our rough estimate is
the ability of AFAP-110 to display enhanced actin filament cross-linking upon
phosphorylation is diminished up to 90 per cent whereas the ability of AFAP-110 to
display enhanced actin filament cross-linking upon phosphorylation is diminished only
up to 50 or 60 per cent. These experiments must be repeated in order to confirm the
accuracy of the first experiment described here. Nonetheless, the data of confocal actin
cross-linking assays performed with AFAP-110 deletion mutants described above points
out that phosphorylation sites playing role in regulation of AFAP-110 function must
reside within amino acids 266-294 of STK region. Serine residues 276,277,281 and 282
are the strongest candidates to be PKCα functional phosphorylation sites. AFAP-110
point mutants having either first or second pair of these serines changed to alanines have
already been created in our lab as well as AFAP-110 mutant, which has all four of these
serine residues mutated to alanines. These mutants are going to be tested in confocal actin
cross-linking assays in order to determine whether they would fail to cross-link
filamentous actin efficiently in response to PKCα phosphorylation in vitro, and also these
mutants along with described above AFAP-110 deletion mutants will be expressed in
cultured cells to determine whether their expression would block actin cytoskeleton
reorganization and motility structure formation induced in response to PKC activation.
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Figure 1. AFAP-110 domain structure
1Amino terminus containing putative Nuclear Export Sequence (NES)
2SH3 binding motif
3Putative WW binding motif
4, 8 - SH2 binding motifs
5, 7 - Pleckstrin Homology (PH) domains
6Serine Threonine Kinase Interaction Region (STK)
9Coil/turn region, unknown function.
10Leucine zipper motif
11- Actin binding regions
12- Carboxy terminus, unknown function.
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Figure 2. Results of phosphotryptic mapping analysis of AFAP-110.
A. Recombinant AFAP-110 was phosphorylated with recombinant PKCα in vitro in the
presence of radiolabeled ATP in a PKC kinase buffer; phosphorylated protein was gelpurified, eluted out of polyacrylamide and subjected to digestion with
trypsin
followed by two-dimensional separation of phosphotryptic peptides on a
Thin Layer
Chromatography (TLC) plate.
B. Cos-1 cells transiently transfected with AFAP-110 were labeled with radioactive
orthophosphate for 16 hours and treated with 100nM PMA for 60 minutes prior to cell
lysis. AFAP-110 was immunoprecipitated from these cell lysates, gel-purified, eluted out
of polyacrylamide and subjected to digestion with trypsin followed by two-dimensional
separation of phosphotryptic peptides on a TLC plate.
C. Cos-1 cells were transiently co-transfected with AFAP-110 and active Src (Src527F),
and labeled with radioactive orthophosphate for 16 hours prior to cell lysis. AFAP-110
was immunoprecipitated from these cell lysates, gel-purified, eluted out of
polyacrylamide and subjected to digestion with trypsin followed by two-dimensional
separation of phosphotryptic peptides on a TLC plate.
D. Recombinant AFAP-110 was phosphorylated with recombinant Src kinase in vitro in
the presence of radiolabeled ATP in an Src kinase buffer; phosphorylated protein was
gel-purified, eluted out of polyacrylamide and subjected to a digestion with trypsin
followed by two-dimensional separation of phosphotryptic peptides on a TLC plate.
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Figure 3. First set of AFAP-110 deletion mutants. Schematic representation of the four
GST-tagged AFAP-110 deletion mutants missing either SH3 binding motif, potential
WW binding motif and amino-terminal SH2 binding motif altogether (represented by
amino acids 62-152), or amino terminal PH domain (represented by amino acids 153248), or STK region (represented by amino acids 246-346), or carboxy terminal PH
domain (represented by amino acids 347- 450).
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Figure 4. Confocal actin filament cross-linking assay with full length AFAP-110.
Rhodamine-labeled filamentous actin was incubated with either non-phosphorylated (A
and B) or PKCα- phosphorylated (C and D) recombinant AFAP-110 in the actin
polymerization buffer. The reactions were plated on microscope slides, covered with
coverslips and analyzed using confocal microscope. Panels A and C represent 10X
magnification; panels B and D – 63X magnification.
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Figure 5. Confocal actin filament cross-linking assay with AFAP-110∆62-152.
Rhodamine-labeled filamentous actin was incubated with either non-phosphorylated (A
and B) or PKCα-phosphorylated (C and D) recombinant AFAP-110∆62-152 in the actin
polymerization buffer. The reactions were plated on microscope slides, covered with
coverslips and analyzed using confocal microscope. Panels A and C represent 10X
magnification; panels B and D – 63X magnification.
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Figure 6. Confocal actin filament cross-linking assay with AFAP-110∆PH1.
Rhodamine-labeled filamentous actin was incubated with either non-phosphorylated (A
and B) or PKCα-phosphorylated (C and D) recombinant AFAP-110∆62-152 in the actin
polymerization buffer. The reactions were plated on microscope slides, covered with
coverslips and analyzed using confocal microscope. Panels A and C represent 10X
magnification; panels B and D – 63X magnification.
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Figure 7. Confocal actin filament cross-linking assay with AFAP-110∆STK.
Rhodamine-labeled filamentous actin was incubated with either non-phosphorylated (A
and B) or PKCα-phosphorylated (C and D) recombinant AFAP-110∆STK in the actin
polymerization buffer. The reactions were plated on microscope slides, covered with
coverslips and analyzed using confocal microscope. Panels A and C represent 10X
magnification; panels B and D – 63X magnification.
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Figure 8. Confocal actin filament cross-linking assay with AFAP-110∆PH2.
Rhodamine-labeled actin filaments were incubated with either non-phosphorylated (A) or
PKCα-phosphorylated (B) recombinant AFAP-110∆PH2 in the actin polymerization
buffer. The reactions were plated on microscope slides, covered with coverslips and
analyzed using confocal microscope at 63X magnification.
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Figure 9. Second set of AFAP-110 deletion mutants. Schematic representation of the
two GST-tagged AFAP-110 deletion mutants missing either first (represented by amino
acids 249-294) or second (represented by amino acids 295-346) half of STK region.
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Figure 10. Confocal actin filament cross-linking assay with AFAP-110∆249-294.
Rhodamine-labeled filamentous actin was incubated with either non-phosphorylated (A
and B) or PKCα-phosphorylated (C and D) recombinant AFAP-110∆249-294 in the actin
polymerization buffer. The reactions were plated on microscope slides, covered with
coverslips and analyzed using confocal microscope. Panels A and C represent 10X
magnification; panels B and D – 63X magnification.
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Figure 11. Confocal actin filament cross-linking assay with AFAP-110∆295-346.
Rhodamine-labeled filamentous actin was incubated with either non-phosphorylated (A
and B) or PKCα-phosphorylated (C and D) recombinant AFAP-110∆295-346 in the actin
polymerization buffer. The reactions were plated on microscope slides, covered with
coverslips and analyzed using confocal microscope. Panels A and C represent 10X
magnification; panels B and D – 63X magnification.
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Figure 12. Third set of AFAP-110 deletion mutants. Schematic representation of the
two GST-tagged AFAP-110 deletion mutants missing either first (represented by amino
acids 249-265) or second (represented by amino acids 266-294) quarter of STK region.
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Figure 13. Confocal actin filament cross-linking assay with AFAP-110∆249-265.
Rhodamine-labeled filamentous actin was incubated with either non-phosphorylated (A)
or PKCα-phosphorylated (B) recombinant AFAP-110∆249-265 in the actin polymerization
buffer. The reactions were plated on microscope slides, covered with coverslips and
analyzed using confocal microscope at 40X magnification.
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Figure 14. Confocal actin filament cross-linking assay with AFAP-110∆266-294.
Rhodamine-labeled filamentous actin was incubated with either non-phosphorylated (A
and B) or PKCα-phosphorylated (C and D) recombinant AFAP-110∆266-294 in the actin
polymerization buffer. The reactions were plated on microscope slides, covered with
coverslips and analyzed using confocal microscope. All panels represent 40X
magnification.
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Chapter 3

Determining whether 14-3-3 is a binding partner
for AFAP-110
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I. Introduction.
14-3-3 proteins represent a group of small acidic proteins with isoelectric point
4.5 and molecular weight around 30kDa. These proteins are expressed ubiquitously and
are known to be present in all species of vertebrates, invertebrates, plants, and fungi (14). 14-3-3 family of proteins includes seven unique isoforms name by Greek letters
according to their elution order after reverse-phase high-performance liquid
chromatography: β/α, ζ/δ, η, γ, τ, σ

and

ε (2;5;6). 14-3-3 proteins are highly

conserved among each other and across different species although they do have
differences in some regions (5). All 14-3-3 proteins have the ability to dimerize; they can
form both homo- and heterodimers in vitro and in vivo (4;7). Dimerization occurs via
hydrophobic interactions between highly conserved residues within amino-terminal parts
of the molecules (2;5;6). Carboxy-termini of two molecules brought together by
dimerization create ligand binding amphipathic groove (8;9). Highly conserved residues
form the inner surface of the binding groove, whereas variable residues create the outer
surface. This groove may bind either two different molecules or bring together different
regions of the same protein allowing 14-3-3 to act as scaffolds or allosteric regulators
(8;10)). The variant residues of the outer surface of the groove may also provide specific
binding surfaces for different proteins (5). 14-3-3 proteins binding groove is specific for
either one of the two well-defined structural motifs on target proteins. First of them
contains phosphoserine (or phosphothreonine) in the center with arginine, serine and
proline in positions –3, –2, and +2, respectively. Second one is defined as a short amino
acid sequence containing phosphoserine/phosphothreonine in the center with arginine,
aromatic residue, basic residue and proline at positions –4, -2, -1, +2 respectively
(6;9;11). Some 14-3-3 binding sequences are known to contain lysine instead of arginine
in –3 or –4 position respective to phosphoserine/phosphothreonine (Dr. Gury Tzivion,
personal communication). 14-3-3 dimers could bind to several phosphoserine-containing
motifs on one protein or bring several target proteins together as a consequence of
binding to conserved motifs found on different proteins. 14-3-3 dimers also may act as
molecular links

between proteins bound to the conserved groove and ones associated

with variable outer surface, therefore performing a role of scaffolds that regulate specific
protein-protein interactions (8). 14-3-3 proteins have been implicated in regulation of
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serine/threonine kinases such Raf and PKC (12-14). 14-3-3 proteins bind Raf and certain
PKC isoforms directly and therefore serve to facilitate interactions between these
signaling proteins (10). Raf is a key protein kinase in mitogen activated protein kinase
(MAPK) cascade. Raf acts downstream of growth factor receptor and Src-family nonreceptor tyrosine kinases, and Ras, and upstream of MAPK kinase to transmit
developmental and proliferative signals. 14-3-3 associates with Raf in vivo regardless of
Raf subcellular localization or activation status (15). Overexpression of 14-3-3 proteins
has been shown to contribute to Raf activation, although it is clear that 14-3-3 proteins
unable to activate Raf by themselves (15). Some other reports stated that the nature of
14-3-3 influence on Raf-1 is inhibitory (16;17). The data on Raf-14-3-3 interaction
accumulated up-to-date suggests the following model of Raf-14-3-3 interaction: Raf has
three 14-3-3 binding sequences in its structure. 14-3-3 is bound to cytosolic Raf at
amino-terminal and carboxy terminal binding sites; this association serves to keep Raf in
inactive although activatable state. Upon Raf activation by Ras the former undergoes
translocation to membrane. 14-3-3 protein is displaced from the amino terminal binding
site on Raf, but it still associates with the carboxy terminal 14-3-3 binding site. Yet
unidentified kinase come along and phosphorylate the serine in the center of intermediate
14-3-3 binding site of Raf and 14-3-3 binds to it, stabilizing Raf in active state (9;14).
14-3-3 therefore has a dual role in Raf regulation. 14-3-3 proteins also have been shown
to be both PKC substrates and regulatory proteins (12;18). At first it was believed that
14-3-3 had inhibitory influence on PKC, this conclusion came mostly from the fact that
PKC inhibitors from brain belong to 14-3-3 family of proteins (19;20). At least three
possible mechanism of inhibitory influence of 14-3-3 upon PKC have been suggested.
14-3-3 proteins have been found to contain a stretch of amino acid residues similar to
PKC pseudosubstrate sequence, which lead to one possible explanation of their
inhibitory influence on PKC. Another possible mechanism of PKC inhibition by 14-3-3
proteins arose from the fact that 14-3-3 contains a stretch of amino acid identical to those
seen in receptors for activated C kinase (RACKs), whose function is to bring active PKC
to membrane and cytoskeletal structures. 14-3-3 interaction with active PKC therefore
thought to interfere with its translocation to membrane and therefore inhibit its function
(2;5). One more possible mechanism came from the observation that 14-3-3 bind to
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cysteine rich domain of PKC which is responsible for interaction with DAG (5). It was
postulated that 14-3-3 binding to PKC prevents its activation by DAG (5). Experiments
conducted by other groups contradict the belief that 14-3-3 inhibit PKC. Studies by Acs
et al and van der Hoeven et al revealed positive influence of 14-3-3 on PKC activity
(12;21). The nature of 14-3-3 influence on PKC activity is controversial but nonetheless
it is apparent that 14-3-3 interacts with PKC. Some 14-3-3 proteins have been shown to
bind phospholipids; this fact suggests that 14-3-3 family facilitate PKC association with
cell membrane (7). 14-3-3 may bind to Raf and PKC at the same time, therefore bringing
Raf to proximity with PKC to ensure phosphorylation of the former by the latter
(6;10;22). Recent reports indicate that 14-3-3 proteins may be involved in regulation of
cytoskeleton organization. 14-3-3 β and γ isoforms have been reported to associate with
actin and be implicated into rearrangements of cortical actin network (23). Expression of
dominant negative 14-3-3 analogs in yeast result in disruption of actin cables (24).
Numerous reports on 14-3-3 that have appeared in recent years indicate that 14-33 proteins act as molecular scaffolds regulating function of signaling proteins by either
changing thei conformation or by assembling them into multiplayer signaling complexes.
14-3-3 proteins also appear to play a role in cytoskeletal remodeling. Discovering
whether 14-3-3 is a binding partner for AFAP-110 may shed light on revealing the new
insight on the mode of AFAP-110 regulation.

74

II. Materials and methods.
Expression vectors: pCMV/AFAP-110 and pCMV/AFAP-110/Src527F were
described in (25;26). pCMV/AFAP-110∆cterm, pCMV/AFAP-110∆lzip, pCMV/AFAP110∆44, pCMV/AFAP-110∆Sfu, pGEX-6p-1-AFAP-110 were described in Qian et al,
accepted. pEBG-GST-14-3-3 and pEBG-GST-CT-14-3-3 were kindly provided by Dr.
Gury Tzivion.
Primers for site directed mutagenesis:
S548A(+): AGCGCACAGCAGCCAATGCAGAACAG
S548A(-): CTGTTCTGCATTGGCTGCTGTGCGCT
S569A(+): AGAGGTTACAGGCCAAGGAAGAGGAAC
S569A(-): GTTCCTCTTCCTTGGCCTGTAACCTCT
Site directed mutagenesis: pCMV/AFAP-110S548a and pCMV/AFAP-110S569a
were created by PCR-based site-directed mutagenesis using primers with nucleotide
mismatches containing desired mutation. Briefly, 20 ng of pCMV/AFAP-110 template
was mixed with 5 ml of 10X reaction buffer (Stratagene), 125 ng of each primer, 1 ul of
10 mM dNTP mix (Stratagene), and 2.5 units of Pfu Turbo DNA polymeraze. The
volume of PCR mix was brought to 50 ml with HPLC grade autoclaved water. The
reactions were overlaid with 30 ml of mineral oil. The ractions were carried out at 95
degrees for 30 seconds, and 18 cycles of 95 degrees at 30 seconds, 55 degrees for 1
minute, and 68 degress for 15 minutes. The reactions were than incubated at 37 degrees
for 1 hour with 10 units of DpnI restriction enzyme (Roche) to digest the template. 1 ul
of each PCR reaction was added to 50 ul of Epicurian coli XL-1 Blue supercompetent
cells and incubated on ice for 30 minutes. The transformation reactions were heat-pulsed
for 45 seconds at 42 degrees, and placed on ice for 2 minutes. After that 0.5 ml of NZYBroth (5 grams of NZ amine, 2.5 grams of yeast extract, 2.5 grams of NaCl were diluted
in 500 ml of MilliQ water and autoclaved. 6.25 ml of 1 M MgCl2 and 6.25 ml of 1 M
MgSO4 and 5 ml of a 2M filter-sterilized glucose solution were added to the autoclaved
broth, and filter-sterilized) preheated to 42 degrees was added to each transformation
reaction, and the reactions were incubated at 37 degrees with shaking for 1 hour. After
that the reactions were plated onto 2X Ampicillin LB plates. Cultures from several
colonies were inoculated for mini-scale DNA preparation, and the extracted DNA was
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screened either by restriction mapping or DNA sequencing to determine which colonies
contain pCMV/110 plasmid vector bearing desired substitution.
Cell culture and transient transfections: Cos-1 cells were maintained in
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 5% Fetal Calf
Serum, 2mM glutamine and 1% penicillin/streptomycin. Cos-1 cells for AFAP-110/14-33 association experiment were transiently co-transfected with AFAP-110 and 14-3-3
constructs using either Modified Calcium Phosphate-mediated Transfection Procedure or
lipofectamine 2000 transfection kit. For Modified Calcium Phosphate-mediated
Transfection Procedure, cells were grown to 60% confluence. 20 µg plasmid DNA for
single transfection or 15 µg of each plasmid for co-transfection were mixed with 0.5 ml
of 0.25M CaCl2. 0.5 ml of 2X BES-buffered saline (50mM BES, 280mM NaCl, 1.5 mM
Na2HPO4x2H2O) was added to DNA dissolved in 0.25M CaCl2, and the mixtures were
incubated for 20 minutes at room temperature to allow complex formation. After that the
mixtures were added to Cos cells in a drop wise manner. Cells were then placed into 3%
CO2 incubator for 16 hours, after which the medium was replaced with fresh growth
medium and cells were allowed to reach confluence. They were lysed at 60-66 hours
after transfection in 1x RIPA lysis buffer (1% NP-40, 0.25 % deoxycholate, 150mM
NaCl, 50mM Tris, pH=7.5 supplemented with protease and phosphatases inhibitors 50
µg/µl aprotinin, 2mM Sodium Vanadate, 2mM PMSF, 2 mM EGTA, 10 µg/ml
Leupeptin). For transfection with lipofectamine2000 reagent Cos-1 cells were grown to
60% confluence on 10 mm cell culture dishes, washed with DMEM supplemented with
2mM glutamine and overlaid with 6 ml Cos-1 culture medium containing 2 µg of 14-3-3
plasmid construct, 3 µg of AFAP-110 plasmid construct, and 25 µl lipofectamine
reagent. In 12-14 hours 6 ml of DMEM supplemented with 20% fetal calf serum, 2mM
glutamine, and 1% penicillin/streptomycin was added to the cells being transfected. Cells
were incubated in this medium for 8-10 hours. Then the media containing the
DNA/lipofectamine mixture was removed and transfected cells were overlaid with 10 ml
of Cos-7 growth media. Cells were lysed at 36 hours after transfection in either NP-40
Lysis Buffer (1% NP-40, 150mM NaCl, 50mM Tris, pH=7.5) supplemented with
protease and phosphatases inhibitors (50 µg/µl aprotinin, 2mM Sodium Vanadate, 2mM
PMSF, 2 mM EGTA, 10 µg/ml Leupeptin)) or 1XRIPA lysis buffer plus inhibitors.
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Gluthathione sepharose affinity absorption: GS beads were washed 4 times
into 1X RIPA lysis buffer. 30 µl of washed beads were added into 1 ml of Cos cell
lysates co-expressing full length or amino-terminally truncated GST tagged 14-3-3 and
either wild type or mutant AFAP-110. Pull down reactions were incubated for 2 hours at
4 degrees with shaking and spun down in tabletop centrifuge; beads were washed twice
in 1XRIPA and once in 1XTBS, resuspended in 2XLSB, boiled for 5 minutes, and
subjected to 10% SDS-PAGE followed by Western transfer to PVDF membrane and
immunoblotting with AFAP-110 reactive antibodies (either 4C3 or F1). In order to
determine GST-14-3-3 expression levels PVDF membranes were stripped for 30 minutes
in stripping buffer (3.5 ml 2-ME, 100 ml 10% SDS, 15.6 ml 1M Tris, pH=6.7, 380.85 ml
milliQ water), at 50 degrees with shaking, washed in TBS-T, blocked in 3% milk and
stained with anti GST antibody. Pull downs were normalized to GST-14-3-3 expression
levels.
Immunoprecipitation: 2 µl polyclonal antibody F1 was added to 1 ml of Cos-1
cell lysates and the reactions were incubated for 1.5 hours at 4 degrees with shaking.
After that 30 µl of protein A agarose was added to immunoprecipitation reaction as a
secondary antibody to pull down F1-AFAP-110 complexes; the reactions were incubated
for 1.5 hours at 4 degrees with shaking. Complexes were then washed twice with
1XRIPA and once with 1XTBS, resuspended in 2XLSB, boiled, and subjected to SDSPAGE followed by transfer to PVDF membrane for western blotting analysis.
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III. Results.
14-3-3 proteins comprise a family of small acidic adaptor proteins, which
recognize consensus sites RSXpS/TXP or RXSXpS/TXP. In order for 14-3-3 proteins to
bind to its target serine or threonine in a position 0 in the center of 14-3-3 binding site
must be phosphorylated, and arginine (or lysine) in –3 or –4 position must be present for
14-3-3 binding to occur, whereas S in –2 position and P in +2 position may be
substituted by any other residue (27).
AFAP-110 contains twelve potential 14-3-3 binding sequences in its structure
(table 1). Amino acids stretches 528-534, 45-550 and 660-666 represent the most valid
candidates to be 14-3-3 binding sites (Dr. Gury Tzivion, personal communication).
Table 1

Number Amino acids Potential 14-3-3 binding sequences
1
2
3
4
5
6
7
8
9
10
11
12

37-43
279-284
304-310
333-339
476-482
528-534
536-541
545-550
565-571
660-666
672-677
703-709

RIQSSKG
RPSSDG
RKKSSKT
KKPSTDE
RVISTNP
RTLNSQP
KPESVS
RTASNA
KRLQSKE
KSGTSSP
KHRTLE
RPPSSNN

Table 2

AFAP-110 mutants
used in co-expression
with 14-3-3

Amino acid stretch
missing

Potential 14-3-3
sequence(s) missing

553-729

9-12

593-729

10-12

AFAP-110∆lzip
AFAP-110∆Sfu

554-592

9

417-723

5-12

AFAP-110∆146-343

146-343

2-4

AFAP-110∆cterm
AFAP-110∆44
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AFAP-110 was immunoprecipitated from Cos-1 cell lysates over expressing
AFAP-110 and subjected to western blotting analysis with anti phospho 14-3-3 binding
motif antibody. Anti phospho 14-3-3 binding motif antibody was immunoreactive with
AFAP-110 derived from Cos cell lysates, either non-treated or subjected to 15 minute
PMA treatment to induce cellular PMA responsive PKC isoforms or co-expressing active
Src (Figure 1). These data indicate that, first of all, AFAP-110 may contain one or
several 14-3-3 binding sequences and second of all, as the antibody is phospho-specific,
suggest that serine/threonine residues in the middle of 14-3-3 binding sequences must be
constitutively phosphorylated. This experiment was repeated three times.
When we established that AFAP-110 contains 14-3-3 binding sites, we decided to
find out whether 14-3-3 associated with AFAP-110 in vivo. In order to answer this
question GST-14-3-3 was co-expressed in Cos cells with AFAP-110. Cells were lysed,
and 30 µl of gluthathione sepharose beads were used to pull down GST-14-3-3. The
beads-GST-14-3-3 complexes were boiled and subjected to SDS-PAGE, followed by
western transfer and staining with anti-AFAP-110 antibody. A 110-kDa band was
visualized on that blot indicating that AFAP-110 associated with 14-3-3 (figure 2). This
experiment was repeated three times.
Next question was to find which region(s) of AFAP-110 is/are responsible for its
association with 14-3-3. It was proposed to co-express GST-14-3-3 with either one of
several existing AFAP-110 deletion mutants missing one or more potential 14-3-3
binding sequences (table 2). The mutant that would fail to associate with 14-3-3 would
therefore be missing sequence(s) facilitating 14-3-3 association with AFAP-110, and
would also suggest the possibility of direct interactions between 14-3-3 and AFAP-110.
First of all, GST-14-3-3 was co-expressed with either full length AFAP110 or truncated version of it missing amino acids 553-729 (AFAP-110∆cterm). AFAP110∆cterm lacks five carboxy-terminally located potential 14-3-3 binding sequences. The
pull down experiments demonstrated that full length AFAP-110 associates with 14-3-3
whereas carboxy terminally truncated AFAP-110 fails to associate with 14-3-3 (figure
3). This experiment was repeated twice.
When we established that AFAP-110 contains 14-3-3 binding sites, we decided to
find out whether 14-3-3 associated with AFAP-110 in vivo. In order to answer this
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question GST-14-3-3 was co-expressed in Cos-1 cells with AFAP-110. Cells were lysed,
and 30 µl of gluthathione sepharose beads were used to affinity absorb GST-14-3-3 from
the cell lysates. Affinity absorptions were normalized to GST-14-3-3 expression levels.
The beads-GST-14-3-3 complexes were then washed twice in lysis buffer and once in
1XTBS buffer, resuspended in 2XLSB, boiled and subjected to SDS-PAGE, followed by
western transfer and staining with anti-AFAP-110 antibody (F1 or 4C3). A 110-kDa
band was visualized on the blot indicating that AFAP-110 associated with 14-3-3 in vivo
(figure 2 - representative of the three experiments).
Next question was to find which region(s) of AFAP-110 responsible for
interaction with 14-3-3. Analysis of amino acid sequence of AFAP-110 reveals the
presence of twelve candidate 14-3-3 target sequences within its structure (table 1). In
order to determine which sequences facilitate AFAP-110 association with 14-3-3 in vivo
it was proposed to co-express GST-14-3-3 with either one of several existing AFAP-110
deletion mutants missing one or more potential 14-3-3 binding sequences (table 2). The
mutant(s) that would fail to associate with 14-3-3 would therefore be missing
sequence(s) facilitating 14-3-3 association with AFAP-110, and would also suggest the
possibility of direct interactions between 14-3-3 and AFAP-110.

First of all, GST-14-

3-3 was co-expressed with either full length AFAP-110 or truncated version of it missing
amino acids 553-729 (AFAP-110∆cterm). AFAP-110∆cterm lacks four carboxy-terminally
located potential 14-3-3 binding sequences. The pull down experiments demonstrated
that full length AFAP-110 associates with 14-3-3 whereas carboxy terminally truncated
AFAP-110 fails to associate with 14-3-3 (figure 3). This experiment was repeated twice.
We included into our following experiments gluthathione sepharose pull down
from cell lysates over expressing GST-Cterm-14-3-3 with full length AFAP-110 as soon
as we received pEBG-GST-Cterm-14-3-3 plasmid from our collaborator Dr. Gury
Tzivion. 14-3-3 mutants containing amino-terminal truncation fail to dimerize, and
therefore in most cases they fail to bind to target proteins for full length 14-3-3. If GSTCterm-14-3-3 would associate with AFAP-110 as well as GST-14-3-3, we would
conclude that AFAP-110 might be one of those few 14-3-3 target proteins, which contain
high affinity 14-3-3 binding sequences. If GST-Cterm-14-3-3 would fail to associate
with AFAP-110, we would therefore be able to use it as a negative control in our pull
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down experiments. Our experiments indicated that GST-Cterm-14-3-3 associates with
AFAP-110 much weaker than full length 14-3-3 (figures 5,6,7). The presence of
background band in our experiments may be explained by the dimerization between Nterminal GST-tags; although GST-facilitated dimerization is much weaker and cannot by
any means compensate for absence of N-terminal helices of 14-3-3.
The failure of GST-14-3-3 to pull down AFAP-110∆cterm suggested that the
carboxy terminal potential 14-3-3 binding sequences of AFAP-110 play an important
role in 14-3-3-AFAP-110 interactions. The deletion of amino acids 553-729 results in
disappearance of four carboxy terminal potential 14-3-3 binding sequences (table 2) and
a possible disruption of potential 14-3-3 binding sequence represented by amino acids
545-550; this sequence is which is one of the three strongest candidates to be the 14-3-3
interaction site on AFAP-110 (Dr. Gury Tzivion, personal communication). Therefore
we have decided to test whether amino acids

545-550 represent 14-3-3 binding site,

responsible for 14-3-3 association with AFAP-110. In order to determine that serine 548
was changed to alanine; this amino acid substitution results in inability of this potential
14-3-3 binding sequence to be phosphorylated and therefore this site can no longer
facilitate AFAP-110 interactions with 14-3-3. Serine residue 569 in the middle of the
neighboring amino acid stretch 565-571 was also changed to alanine, and either one of
the two site-directed mutants were co-expressed with GST-14-3-3 in cultured cells. In
order to test whether either one or both of these mutants would fail to associate with 143-3 we pull down GST-14-3-3 from the cell lysates and performed western blotting
analysis with anti-AFAP-110 antibody 4C3 (Fugure4). This experiment indicated that
AFAP-110s548a mutant associates with AFAP-110 weaker than either wild type or AFAP110s569a mutant (figure 5).

Surprisingly, this experiment has shown that AFAP-

110deltacterm, included as a negative control for AFAP-110 association with 14-3-3,
associates with 14-3-3 better than full length AFAP-110 and any other AFAP-110
mutant included into this assay (figure 5). This contradicts the earlier data, which
indicate that AFAP-110delta cterm cannot associate with 14-3-3. Since then we
performed more experiments to determine whether c-terminally truncated AFAP-110
fails to associate with 14-3-3. Three out of seven gluthathione sepharose pull down
assays indicate that AFAP-110delta cterm fails to associate with GST-14-3-3 (figure 3 -
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representative of two experiments, figure5), whereas four out of seven experiments
demonstrate that AFAP-110 delta cterm associates with 14-3-3 better than wild type
(figures 4,6,7,8). We also performed gluthathione sepharose pull down assays from the
cell lysates over expressing GST-14-3-3 (or even GST-Cterm-14-3-3) with wild type
AFAP-110 or AFAP-110 deletion mutants missing one or several prospective 14-3-3
binding sequences (table 2). We failed to get consistent results with these mutants as
well. For example, in figure 5 we see that AFAP-110∆lzip associates with GST-14-3-3
better than AFAP-110 full length and any other mutant, and that even GST-Cterm-14-3-3
strongly interacts with AFAP-110∆lzip, whereas the very next experiment indicates just
the opposite - that AFAP-110∆lzip fails to associate with 14-3-3 (figure 6). The same can
be said about interactions of GST-14-3-3 with any other AFAP-110 deletion mutant used
in these assays shown in figures 5 through 7. Therefore we have decided to drop this
project at this point. We have determined that 14-3-3 and AFAP-110 associate in vivo,
although it is still unclear whether this association is direct or indirect. It remains to be
determined which sequence(s) within AFAP-110 structure facilitate AFAP-110
interaction with 14-3-3 in vivo.
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IV. Discussion.
14-3-3 proteins comprise a group of small acidic proteins, which act as adaptor
proteins in living cells; due to their ability to form dimers they can regulate function of
signaling proteins by either changing their conformation or bringing several different
proteins into multi-protein signaling complexes (27). 14-3-3 proteins are expressed
ubiquitously, and are known to bind to over sixty cellular proteins via well-defined target
motifs RSXpS/TXP or RXSXpS/TXP containing phosphorylated serine or threonine
residue in the middle thereby regulating their function (28). In this work we tried to
determine whether actin filament associated protein AFAP-110 is a binding partner for
14-3-3. AFAP-110 is an actin filament cross-linking protein with an intrinsic ability to
remodel actin in response to Src/PKC signaling; 14-3-3 association with AFAP-110
could link AFAP-110 to Raf-MAPK cascade or stabilize AFAP-110 interactions with
PKC in the same manner as 14-3-3 brings PKC and Raf together into close proximity.
Western blotting analysis of AFAP-110 with anti-14-3-3 binding site antibody
suggested that AFAP-110 is a possible binding partner for 14-3-3 (Figure 1).
Gluthathione sepharose pull down assays from cell lysates co-expressing GST-tagged
14-3-3 and AFAP-110 indicate the possibility of in vivo association of these two
proteins. Analysis of amino acid sequence of AFAP-110 demonstrates that there are
twelve prospective 14-3-3 binding sequences within AFAP-110 structure (table1). In
order to determine which sequences facilitate AFAP-110 association with 14-3-3 in vivo
we co-expressed GST-14-3-3 with either full length AFAP-110 or either one of five
AFAP-110 deletion mutants (table 2). We were trying to determine which deletion would
result in inability of AFAP-110 to associate with 14-3-3; AFAP-110 mutant, which
would fail to associate with GST-14-3-3, would therefore miss 14-3-3 binding site(s)
responsible for 14-3-3 interactions with AFAP-110. Inability of a deletion mutant to
associate with 14-3-3 would suggest the possibility of direct interaction between AFAP110 and 14-3-3. At first the data was indicating that AFAP-110∆cterm fails to associate
with 14-3-3, and we thought that one of the four carboxy-terminal potential14-3-3
binding sequences of AFAP-110 facilitate interactions with 14-3-3. It was also possible
that the carboxy-terminal truncation of AFAP-110 alters a strong potential 14-3-3
interaction site delineated by amino acids 545-550, so the AFAP-110 mutant that has
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serine in the middle of this site substituted by alanine residue was created to test the
importance of this particular sequence in AFAP-110 interactions with 14-3-3. We also
made another site-directed mutant of AFAP-110 by substitution of serine residue (s569)
in the middle of neighboring prospective 14-3-3 binding sequence delineated by amino
acids 565-571. This is the most amino terminal of four potential 14-3-3 binding sites,
which are completely missing in AFAP-110∆cterm. We decided to compare effects of
these two amino acid substitutions on AFAP-110 associations with 14-3-3. GST-14-3-3
pull down assays have shown that neither one of these mutants fail to associate with 143-3 although GST-14-3-3 associates with AFAP-110s548a weaker than with either wild
type AFAP-110 or AFAP-110s569a. Therefore, amino acids 545-550 may represent one of
the pivotal 14-3-3 interaction sequences within AFAP-110 structure, but certainly not the
only one. More experiments are required to determine the significance of this particular
sequence in AFAP-110-14-3-3 interactions.
Further experiments have demonstrated that AFAP-110 delta cterm interacts with
GST-14-3-3 better than full length AFAP-110, which did not agree with the previous
data. In order to determine whether AFAP-110∆cterm associates with 14-3-3 better or
worse than full length AFAP-110 more gluthathione sepharose affinity absorptions of
GST-14-3-3 from cell lysates co-expressing GST-14-3-3 and AFAP-110 or AFAP110∆cterm or any other existing AFAP-110 deletion mutants were performed. The results
were controversial for all the deletion mutants used in these experiments; for example, in
case of GST-14-3-3 and AFAP-110∆cterm co-expressions the results of the three pull down
assays inducate failure of AFAP-110 cterm to associate with 14-3-3 whereas the results
of four pull down assays demonstrate that AFAP-110∆cterm associates with 14-3-3 much
better than full length AFAP-110. It is uncertain at this point whether the loss of cterminus, or deletion of leucine zipper or any other region of AFAP-110 (table 2) has
positive or negative effect on ability of AFAP-110 to associate with 14-3-3 in vivo. The
controversy of results of our pull down experiments may be explained by the differences
in phosphorylation level of AFAP-110 at the time when the cells were lysed, as it is
known

that

14-3-3

binding

is

phosphorylation

dependent;

serine/threonine

phosphorylation is also known to induce conformational change of AFAP-110, therefore
the variations in phosphorylation levels and conformation of AFAP-110 at the time of
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cell lysis may be responsible for the lack of consistency in our pull down assays. 14-3-3
proteins are known to interact with over 60 binding partners in living cells (28), and the
binding of 14-3-3 proteins to their targets does not always occur via interactions of inner
surface of 14-3-3 binding groove with phosphoserine-containing consensus sites
RSXpS/TXP or RXSXpS/TXP. For example, 14-3-3 is known to bind to adaptor protein
IRS-1 in phosphospecific manner despite the fact that IRS-1 contains no 14-3-3 binding
consensus sequences such as RSXpS/TXP or RXSXpS/TXP (27). In some cases the
interaction with target protein may occur on the outer surface of 14-3-3 binding groove
(9). In the latter case it is unknown which sequences on target proteins facilitate its
interactions with 14-3-3, and 14-3-3 binding in this case is likely to be phosphorylationindependent.
In conclusion it can be said that our experiments indicated that AFAP-110
associates with 14-3-3 in vivo, although it still remains unclear whether this association
is direct or facilitated by one or more of 60 14-3-3 binding partners. In order to
determine whether AFAP-110 interacts with 14-3-3 directly we would need to perform
affinity absorption of purified AFAP-110 with purified 14-3-3 and vice versa; for this
experiment we would need both proteins to be purified from mammalian cells, so they
would be in proper conformation and contain proper post-translational modifications,
which will most likely be absent in proteins expressed in bacterial cells. We do not have
all the necessary equipment to perform this kind of experiment at this time, so this
project must be postponed until this kind of equipment is available.
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Figures and legends.

1

2

3

110kDa

110kDa

Figure 1. Cos-1 cells were transiently transfected with AFAP-110 with no treatment
(lane 1), AFAP-110 with Src527F (lane2), or AFAP-110 along treated with 100nM PMA
for 1 hour (lane3). AFAP-110 was immunoprecipitated from these cells and subjected to
SDS-PAGE followed by Western transfer and staining with anti 14-3-3 binding site
antibody (upper panel). Blot was stripped and reprobed with 4C3 antibody to determine
AFAP-110 expression levels (lower panel).
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1 2 3
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Figure 2. Cos-1 cells were transiently transfected with either GST-14-3-3 alone or
AFAP-110 alone (lanes 1 and 3 respectively in both panels) or co-transfected with both
GST-14-3-3 and AFAP-110 (lane 2 in both panels). A. GST-14-3-3 was pulled down
from cell lysates with gluthathione sepharose beads and subjected to SDS-PAGE
followed by western blotting with F1 antibody. Pull down assay was normalized to GST14-3-3 levels. B. AFAP-110 expression levels in cells lysates used in panel A.
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GST-14-3-3
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1

2

3

AFAP-110
AFAP-110∆cterm

GST-14-3-3

Figure 3. Cos-1 cells were transiently transfected with either GST-14-3-3 alone (lane 1 in
both panels) or co-transfected with GST-14-3-3 with either full length AFAP-110 (lane 2
in both panels) or AFAP-110∆cterm (lane 3 in both panels). GST-14-3-3 was pulled down
from cell lysates with gluthathione sepharose beads and subjected to SDS-PAGE
followed by western blotting with anti-AFAP-110 antibody F1. Pull down assay was
normalized to GST-14-3-3 levels. B. AFAP-110 expression levels in cells lysates used in
panel A.
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AFAP-110

GST-14-3-3
GST-CT-14-3-3

GST

Figure 4. Upper panel - F1 blot of gluthathione sepharose pull down of GST-14-3-3 from
Cos-1 cell lysates co-expressing 1 – GST and full length AFAP-110, 2- GST-CT-14-3-3
and full length AFAP-110, 3- GST-14-3-3 and full length AFAP-110, 4- GST-14-3-3 and
full length AFAP-110 along with active Src (Scr527F), 5- GST-14-3-3 and AFAP-110∆lzip,
6- GST-14-3-3 and AFAP-110∆cterm, 7-GST-14-3-3 and AFAP-110s548a, 8- GST-14-3-3
and AFAP-110s569a. Lower panel represents GST, GST-CT-14-3-3 and GST-14-3-3
levels to which the pull down assays were normalized.
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AFAP-110

GST-14-3-3
GST-CT-14-3-3

Figure 5. Upper panels – 4C3 blot of gluthathione sepharose pull down of GST-14-3-3
from Cos-1 cell lysates co-expressing 1 - GST-CT-14-3-3 and full length AFAP-110, 2GST-14-3-3 and full length AFAP-110, 3- GST-14-3-3 and AFAP-110∆lzip, 4- GST-14-33 and AFAP-110∆cterm, 5- GST-14-3-3 and AFAP-110Sfu∆, 6- GST-14-3-3 and AFAP110∆44, 7- GST-14-3-3 and AFAP-110s548a, 8- GST-14-3-3 and full length AFAP-110
along with active Src (Scr527F), 9- rainbow weight markers, 10- GST-CT-14-3-3 and
AFAP-110∆lzip, 11- GST-CT-14-3-3 and AFAP-110∆cterm, 12- GST-CT-14-3-3 and
AFAP-110Sfu∆, 13- GST-CT-14-3-3 and AFAP-110∆44. Lower panels represent GST-143-3 and GST-CT-14-3-3 levels to which the pull down assays were normalized.
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Figure 6. Upper panel - 4C3 blot of gluthathione sepharose affinity absorption of GST14-3-3 from Cos-1 cell lysates co-expressing 1 – GST and full length AFAP-110, 2GST-CT-14-3-3 and full length AFAP-110, 3- GST-14-3-3 and full length AFAP-110, 4GST-14-3-3 and AFAP-110∆lzip, 5- GST-14-3-3 and AFAP-110∆cterm, 6- GST-14-3-3 and
AFAP-110∆44. Lower panels represent GST, GST-14-3-3 or GST-CT-14-3-3 levels to
which the affinity absorption assays were normalized.
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Figure 7. Upper panel - 4C3 blot of gluthathione sepharose affinity absorption of GST14-3-3 from Cos-1 cell lysates co-expressing: 1 - GST-CT-14-3-3 and full length AFAP110, 2- GST-14-3-3 and full length AFAP-110, 3- GST-14-3-3 and AFAP-110∆lzip, 4GST-14-3-3 and AFAP-110∆cterm, 5- GST-14-3-3 and AFAP-110Sfu∆, 6- GST-14-3-3 and
AFAP-110∆146-343, 7 - GST-14-3-3 and AFAP-110s548a, 8- GST-14-3-3 and AFAP110∆44, 9- GST-14-3-3 and AFAP-110s569a, 10 –GST-14-3-3 and full length AFAP-110
along with active Src (Scr527F). Lower panels represent GST-14-3-3 and GST-CT-14-3-3
levels to which the affinity absorption assays were normalized.
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GST-CT-14-3-3

Figure 8. Cos cells were co-transfected with GST-CT-14-3-3 and AFAP-110 (lanes 1),
GST-14-3-3 and AFAP-110 (lanes2) or GST-14-3-3 and AFAP-110∆cterm. A. Western
blots of gluthathione sepharose affinity absorption of GST-CT-14-3-3 or GST-14-3-3
from Cos cell lysates. Upper panel represents 4C3 western blot; lower panel shows the
same blot as in upper panel striped and reprobed with anti-GST antibody to visualize CT14-3-3 and 14-3-3 levels. B. Western blot for expression levels of AFAP-110 (upper
panel, 4C3 antibody staining) and GST-CT-14-3-3 and GST-14-3-3 (lower panel, antiGST antibody staining).
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Chapter 4

General discussion
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AFAP-110 was discovered in late eighties as a protein that associates with active
Src in v-Src-transformed chicken embryo fibroblast cells (1). AFAP-110 co-localizes
with actin stress fibers as well as cortical actin cytoskeleton in normal cells and with actin
rosettes in Src transformed cells. As AFAP-110 is hyperphosphorylated in response to
co-expression with active Src and also has the ability to associate with this non-receptor
tyrosine kinase, it was proposed that AFAP-110 might be an effector protein for Src that
remodels actin cytoskeleton in response to Src activation by extracellular stimuli (2).
AFAP-110 contains several protein-protein interaction modules, which enable this
protein to bind to other proteins such as filamentous actin and cellular kinases Src and
PKC. AFAP-110 also possesses the ability to multimerize via carboxy-terminal leucine
zipper motif. The deletion of carboxy terminal leucine zipper motif enables AFAP-110 to
disorganize actin cytoskeleton resulting in a phenotype resembling the consequences of
active Src over expression characterized by actin filament repositioning into actin
rosettes. AFAP-110 therefore possesses an intrinsic ability to remodel actin cytoskeleton.
In recent years it has been determined that AFAP-110 is an actin cross-linking
protein, and that actin cross-linking ability of AFAP-110 is regulated by serine/threonine
phosphorylation (Qian et al, accepted). AFAP-110 actin cross-linking properties are
dependent on its multimerization status; non-phosphorylated AFAP-110 is thought to
exist in a form of large multimeric complexes cross-linking filamentous actin into a
lattice of loosely interconnecting actin fibers whereas phosphorylated AFAP-110 is
thought to exist only in a form of dimers and cross-link actin filaments into a network of
short bundles (Qian et al, accepted). AFAP-110 ability to self-associate is regulated by
serine/threonine phosphorylation in PKC dependent manner (Baisden and Flynn,
unpublished data). Therefore it became important to identify serine and threonine
residues within AFAP-110 structure phosphorylation of which induces changes in AFAP110 conformation resulting in altered mode of self-association and consequently in
enhancement of actin cross-linking properties of AFAP-110. Identification of functional
phosphorylation sites of AFAP-110 was an objective of the first project, described in
chapter 2 of this thesis.
Firstly, we performed phosphotryptic-mapping analysis of AFAP-110 either
recombinant phosphorylated by PKCα in vitro or AFAP-110 derived from radio labeled
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cultured cells either expressing active Src or treated with PKC activator PMA. We
determined that PKCα phosphorylates AFAP-110 on multiple residues in vitro and also
that two of the fragments on the maps of in vivo derived AFAP-110 are likely to be
products of PKC dependent phosphorylation in vivo.
Secondly, we performed PCR-based deletional mutagenesis to determine which
domains of AFAP-110 are the most likely to contain functional phosphorylation sites as
the analysis of AFAP-110 amino acid sequence revealed over twenty PKC consensus
phosphorylation sequences. Confocal actin filament cross-linking assays developed by
Qian and colleagues (Qian et al, accepted) were used as a test for AFAP-110
phosphorylation-regulated function. Wild type AFAP-110 cross-links actin filaments into
loose lattices when non-phosphorylated, but, once it is phosphorylated, this protein
arranges actin filaments into more efficiently cross-linked actin filament aggregates. In
our experiments with AFAP-110 deletion mutants we were looking whether any of them
would fail to display increase in actin cross-linking efficiency upon phosphorylation.
Such a mutant was found; it is an AFAP-110 deletion mutant missing amino acids 249346 comprising Serine Threonine Kinase Interaction (STK) region.
There are nine prospective PKC phosphorylation sites within STK region,
therefore two more deletional mutants were created, each missing either first (amino
acids 249-294) or second half (amino acids 295-346) of STK region. The deletion of
amino terminal half of STK region abrogated PKCα-dependent increase in actin filament
cross-linking efficiency of AFAP-110, whereas the deletion of carboxy-terminal half of
STK region did not have any effect on PKCα-dependent increase in actin filament crosslinking efficiency of AFAP-110. Therefore we draw a conclusion that functional
phosphorylation sites of AFAP-110 must reside within amino acid stretch 249-294. There
are six candidate sites in this region; therefore we created two more deletion mutants
missing either first (amino acids 249-265) or second (amino acids 266-294) quarter of
STK region to narrow down to the region containing not more than four potential sites.
Our data suggests that four serine residues within amino acid stretch 266-294 are the
most likely candidates to be functional PKC phosphorylation sites responsible for
phosphorylation-regulated AFAP-110 function. These residues are being altered by sitedirected mutagenesis either all at once or in pairs. Future experiments will determine
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whether some or all of these serine residues are AFAP-110 functional phosphorylation
sites. Phosphotryptic mapping analysis will determine if these serine residues are
phosphorylated in vitro versus in vivo. The mutants will also be tested in in vitro actin
filament cross-linking assays to determine whether a loss of all the four serine residues or
either serine pair would result in inability of PKCα to enhance actin cross-linking
properties of AFAP-110. These mutants will also be expressed in cultured cells to
determine whether any of them would block the effects of active PKC on actin
cytoskeleton.
The objective of the second project described in chapter three was to determine
whether AFAP-110 is a binding partner for 14-3-3. 14-3-3 proteins are a family of small
acidic proteins originally discovered as brain proteins in 1967 (Moore and Perez, 1967).
By now it is known that these proteins are expressed ubiquitously and are common to
every known organism studied up to date. They have no catalytic function of their own
but nevertheless play an important role in cellular signal transduction pathways because
of their ability to act as scaffolds and/or allosteric regulators for signaling proteins due to
their ability to form dimers (3). 14-3-3 proteins dimerize via interaction between their
amino terminal parts and bind to target proteins via highly conserved carboxy terminally
located binding grooves, which are know to recognize specific target sequences in
phosphorylation-dependent manner. These target sequences usually have phosphorylated
serine or threonine in the middle, position 0, with basic amino acid in position –3 or –4
and proline in position +2. The basic amino acid in –4 or –3 position in most case is
arginine but sometimes it can be substituted by lysine. Basic amino acid in position –4 or
–3 as well as phosphorylation of serine/threonine in position 0 are required for 14-3-3
binding to occur, whereas proline in position +2 is preferred but no absolutely required.
There are certain preferences in other positions surrounding the central phosphorylated
serine/threonine but neither of them as crucial as the presence of basic residue in position
–4 or –3 or requirement for phosphorylation of the central serine/threonine. Binding
groove of 14-3-3 proteins in fact was the first serine/threonine phosphorylation-binding
domain discovered and nowadays it remains the best-studied phospho-serine/threonine
binding module.
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14-3-3 binds a wide variety of proteins participating in different cellular
pathways, among which are serine/threonine kinases Raf, PKC and Bcr, cellular adaptor
proteins IRS-1, Gab1, and p66Shc, apoptotic protein Bad, cdc25C phosphatase and others
(4;5) We proposed to determine whether AFAP-110 would be a binding partment for 143-3.
First of all, by Western blotting analysis of cellular AFAP-110 with phosphospecific anti-14-3-3 binding site antibody we determined that AFAP-110 contains 14-3-3
binding sequence(s). By the next experiment demonstrated that 14-3-3 and AFAP-110
are associated in vivo, although it remained unknown whether the two proteins bind to
each other directly or via some other cellular adaptor. Analysis of AFAP-110 amino acid
sequence revealed the presence of twelve potential 14-3-3 binding sequences in its
structure, three of which were better candidates comparing to the remaining nine
according to Dr. Gury Tzivion (personal communication).
When we have shown that AFAP-110 associates with 14-3-3 in vivo, we have
decided to find out which regions of AFAP-110 make this interaction possible. It was
decided to co-express different AFAP-110 deletion mutant missing one or several
potential 14-3-3 binding sequences in order to determine which deletion if any results in
abrogation of AFAP-110 association with 14-3-3. The mutant that would fail to associate
with 14-3-3 in vivo would do so either because it lacks important 14-3-3 binding site(s) or
simply because deletion of a certain region results in altered AFAP-110 conformation so
that 14-3-3 can no longer associate with AFAP-110. Once such a mutant was found, we
would have used PCR-based site directed mutagenesis to substitute serine/threonine
residue(s) in the middle of important 14-3-3 binding site(s) to alanines to determine
whether AFAP-110 inability to associate with 14-3-3 is a result of disappearance of
pivotal 14-3-3 binding sequence or merely the consequence of conformational change. If
we would find that the disappearance of 14-3-3 binding site(s) as a result of deletion or
site directed mutation is responsible for abrogation of 14-3-3 association with 14-3-3, we
would have, first of all, found which 14-3-3 binding sequences within AFAP-110
structure make 14-3-3-AFAP-110 interactions possible, and, would get a strong
suggestion that 14-3-3 binds AFAP-110 directly.
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Either one out of several AFAP-110 deletion mutants were co-expressed with
GST-14-3-3 in cultured cells, and gluthathione sepharose affinity absorption of GST-143-3 followed by western blotting with anti-AFAP-110 antibodies were performed in order
to determine which AFAP-110 mutant fails to associate with 14-3-3. Neither of AFAP110 deletion mutants used in our experiments consistently failed to associate with 14-3-3.
This may occur due to a number of reasons. First of all, association of AFAP-110 with
14-3-3 may be indirect, and there is a third, yet unidentified protein that facilitated
AFAP-110 interactions with 14-3-3. Second of all, 14-3-3 does not always bind to well
defined RSXpSXP or RXXXpSXP sequences. 14-3-3 is known to bind in
phosphorylation-dependent manner to proteins such as IRS-1, vimentin, Wee1, and IGFI, although neither of these proteins contains either one of well-defined 14-3-3 binding
sequences (Tzivion and Avruch, 2001). 14-3-3 may also bind to target proteins via
variable outer surface of binding groove.
Thus, we have determined that AFAP-110 associates with full length 14-3-3 in
vivo, whereas association of monomeric 14-3-3 with AFAP-110 is very weak, almost at
the background level. It still remains to be determined whether AFAP-110 and 14-3-3
associate directly and, if yes, whether 14-3-3 interactions with AFAP-110 are
phosphorylation dependent and facilitated by any of the twelve conventional sequences
defined as RSXpSXP or RXXXpSXP.
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